{ "version": "2.2", "instance": { "legn-20260630.htm": { "nsprefix": "legn", "nsuri": "http://legendbiotech.com/20260630", "dts": { "inline": { "local": [ "legn-20260630.htm" ] }, "schema": { "local": [ "legn-20260630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/2023/calculation-1.1.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd", "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions-ea/rol_ifrs_ea-dim_2025-03-27.xsd", "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions/rol_full_ifrs-dim_2025-03-27.xsd", "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd", "https://xbrl.sec.gov/country/2025/country-2025.xsd", "https://xbrl.sec.gov/dei/2025/dei-2025.xsd" ] }, "calculationLink": { "local": [ "legn-20260630_cal.xml" ] }, "definitionLink": { "local": [ "legn-20260630_def.xml" ], "remote": [ "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions-ea/dim_ifrs_ea_2025-03-27_role-995000.xml", "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions/dim_full_ifrs_2025-03-27_role-995000.xml" ] }, "labelLink": { "local": [ "legn-20260630_lab.xml" ] }, "presentationLink": { "local": [ "legn-20260630_pre.xml" ] } }, "keyStandard": 123, "keyCustom": 57, "axisStandard": 10, "axisCustom": 0, "memberStandard": 13, "memberCustom": 7, "hidden": { "total": 6, "http://xbrl.sec.gov/dei/2025": 6 }, "contextCount": 85, "entityCount": 1, "segmentCount": 20, "elementCount": 278, "unitCount": 4, "baseTaxonomies": { "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full": 353, "http://xbrl.sec.gov/dei/2025": 8 }, "report": { "R1": { "role": "http://legendbiotech.com/role/COVER", "longName": "0000001 - Document - COVER", "shortName": "COVER", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20260630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20260630.htm", "first": true, "unique": true } }, "R2": { "role": "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOMELOSS", "longName": "9952151 - Statement - UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME/(LOSS)", "shortName": "UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME/(LOSS)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c-2", "name": "legn:CollaborationRevenue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfGeographicalAreasExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20260630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-2", "name": "ifrs-full:Revenue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20260630.htm", "unique": true } }, "R3": { "role": "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION", "longName": "9952152 - Statement - UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION", "shortName": "UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-5", "name": "ifrs-full:PropertyPlantAndEquipment", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20260630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "ifrs-full:PropertyPlantAndEquipment", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20260630.htm", "first": true, "unique": true } }, "R4": { "role": "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY", "longName": "9952153 - Statement - UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY", "shortName": "UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-12", "name": "ifrs-full:Equity", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20260630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-12", "name": "ifrs-full:Equity", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20260630.htm", "first": true, "unique": true } }, "R5": { "role": "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "longName": "9952154 - Statement - UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "shortName": "UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:ProfitLossBeforeTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20260630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:AdjustmentsForFinanceIncome", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20260630.htm", "unique": true } }, "R6": { "role": "http://legendbiotech.com/role/CORPORATEINFORMATION", "longName": "9952155 - Disclosure - CORPORATE INFORMATION", "shortName": "CORPORATE INFORMATION", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "6", "firstAnchor": { "contextRef": "c-1", "name": "legn:DisclosureOfNotesAndOtherExplanatoryInformationExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20260630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "legn:DisclosureOfNotesAndOtherExplanatoryInformationExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20260630.htm", "first": true, "unique": true } }, "R7": { "role": "http://legendbiotech.com/role/BASISOFPREPARATION", "longName": "9952156 - Disclosure - BASIS OF PREPARATION", "shortName": "BASIS OF PREPARATION", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20260630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20260630.htm", "first": true, "unique": true } }, "R8": { "role": "http://legendbiotech.com/role/NEWSTANDARDSINTERPRETATIONSANDAMENDMENTSADOPTEDBYTHECOMPANY", "longName": "9952157 - Disclosure - NEW STANDARDS, INTERPRETATIONS AND AMENDMENTS ADOPTED BY THE COMPANY", "shortName": "NEW STANDARDS, INTERPRETATIONS AND AMENDMENTS ADOPTED BY THE COMPANY", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20260630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20260630.htm", "first": true, "unique": true } }, "R9": { "role": "http://legendbiotech.com/role/REVENUE", "longName": "9952158 - Disclosure - REVENUE", "shortName": "REVENUE", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfRevenueExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20260630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfRevenueExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20260630.htm", "first": true, "unique": true } }, "R10": { "role": "http://legendbiotech.com/role/OTHEREXPENSENET", "longName": "9952159 - Disclosure - OTHER EXPENSE, NET", "shortName": "OTHER EXPENSE, NET", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfOtherOperatingIncomeExpenseExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20260630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfOtherOperatingIncomeExpenseExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20260630.htm", "first": true, "unique": true } }, "R11": { "role": "http://legendbiotech.com/role/EARNINGSLOSSPERSHARE", "longName": "9952160 - Disclosure - EARNINGS (LOSS) PER SHARE", "shortName": "EARNINGS (LOSS) PER SHARE", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20260630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20260630.htm", "first": true, "unique": true } }, "R12": { "role": "http://legendbiotech.com/role/LEASES", "longName": "9952161 - Disclosure - LEASES", "shortName": "LEASES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfLeasesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20260630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfLeasesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20260630.htm", "first": true, "unique": true } }, "R13": { "role": "http://legendbiotech.com/role/COLLABORATIONINVENTORIESNET", "longName": "9952162 - Disclosure - COLLABORATION INVENTORIES, NET", "shortName": "COLLABORATION INVENTORIES, NET", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfInventoriesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20260630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfInventoriesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20260630.htm", "first": true, "unique": true } }, "R14": { "role": "http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETS", "longName": "9952163 - Disclosure - PREPAYMENTS, OTHER RECEIVABLES AND OTHER ASSETS", "shortName": "PREPAYMENTS, OTHER RECEIVABLES AND OTHER ASSETS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "legn:DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20260630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "legn:DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20260630.htm", "first": true, "unique": true } }, "R15": { "role": "http://legendbiotech.com/role/INCOMETAX", "longName": "9952164 - Disclosure - INCOME TAX", "shortName": "INCOME TAX", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20260630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20260630.htm", "first": true, "unique": true } }, "R16": { "role": "http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDING", "longName": "9952165 - Disclosure - COLLABORATION INTEREST-BEARING ADVANCED FUNDING", "shortName": "COLLABORATION INTEREST-BEARING ADVANCED FUNDING", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfBorrowingsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20260630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfBorrowingsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20260630.htm", "first": true, "unique": true } }, "R17": { "role": "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUM", "longName": "9952166 - Disclosure - SHARE CAPITAL AND SHARE PREMIUM", "shortName": "SHARE CAPITAL AND SHARE PREMIUM", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20260630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20260630.htm", "first": true, "unique": true } }, "R18": { "role": "http://legendbiotech.com/role/OTHERPAYABLESANDACCRUALS", "longName": "9952167 - Disclosure - OTHER PAYABLES AND ACCRUALS", "shortName": "OTHER PAYABLES AND ACCRUALS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "legn:DisclosureOfOtherPayablesAndAccrualsExplanatoryTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20260630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "legn:DisclosureOfOtherPayablesAndAccrualsExplanatoryTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20260630.htm", "first": true, "unique": true } }, "R19": { "role": "http://legendbiotech.com/role/APPROVALOFTHEINTERIMCONDENSEDCONSOLIDATEDFINANCIALSTATEMENTS", "longName": "9952168 - Disclosure - APPROVAL OF THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS", "shortName": "APPROVAL OF THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfAuthorisationOfFinancialStatementsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20260630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfAuthorisationOfFinancialStatementsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20260630.htm", "first": true, "unique": true } }, "R20": { "role": "http://legendbiotech.com/role/REVENUETables", "longName": "9955511 - Disclosure - REVENUE (Tables)", "shortName": "REVENUE (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20260630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20260630.htm", "first": true, "unique": true } }, "R21": { "role": "http://legendbiotech.com/role/OTHEREXPENSENETTables", "longName": "9955512 - Disclosure - OTHER EXPENSE, NET (Tables)", "shortName": "OTHER EXPENSE, NET (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "legn:DisclosureOfDetailedInformationAboutOtherIncomeExpenseTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "legn-20260630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "legn:DisclosureOfDetailedInformationAboutOtherIncomeExpenseTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "legn-20260630.htm", "first": true, "unique": true } }, "R22": { "role": "http://legendbiotech.com/role/EARNINGSLOSSPERSHARETables", "longName": "9955513 - Disclosure - EARNINGS (LOSS) PER SHARE (Tables)", "shortName": "EARNINGS (LOSS) PER SHARE (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:EarningsPerShareExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20260630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:EarningsPerShareExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20260630.htm", "first": true, "unique": true } }, "R23": { "role": "http://legendbiotech.com/role/LEASESTables", "longName": "9955514 - Disclosure - LEASES (Tables)", "shortName": "LEASES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20260630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20260630.htm", "first": true, "unique": true } }, "R24": { "role": "http://legendbiotech.com/role/COLLABORATIONINVENTORIESNETTables", "longName": "9955515 - Disclosure - COLLABORATION INVENTORIES, NET (Tables)", "shortName": "COLLABORATION INVENTORIES, NET (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "legn:DisclosureOfDetailedInformationAboutInventoriesExplanatoryTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20260630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "legn:DisclosureOfDetailedInformationAboutInventoriesExplanatoryTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20260630.htm", "first": true, "unique": true } }, "R25": { "role": "http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSTables", "longName": "9955516 - Disclosure - PREPAYMENTS, OTHER RECEIVABLES AND OTHER ASSETS (Tables)", "shortName": "PREPAYMENTS, OTHER RECEIVABLES AND OTHER ASSETS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "legn:DisclosureOfDetailedInformationAboutPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20260630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "legn:DisclosureOfDetailedInformationAboutPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20260630.htm", "first": true, "unique": true } }, "R26": { "role": "http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGTables", "longName": "9955517 - Disclosure - COLLABORATION INTEREST-BEARING ADVANCED FUNDING (Tables)", "shortName": "COLLABORATION INTEREST-BEARING ADVANCED FUNDING (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "legn-20260630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "legn-20260630.htm", "first": true, "unique": true } }, "R27": { "role": "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMTables", "longName": "9955518 - Disclosure - SHARE CAPITAL AND SHARE PREMIUM (Tables)", "shortName": "SHARE CAPITAL AND SHARE PREMIUM (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20260630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20260630.htm", "first": true, "unique": true } }, "R28": { "role": "http://legendbiotech.com/role/OTHERPAYABLESANDACCRUALSTables", "longName": "9955519 - Disclosure - OTHER PAYABLES AND ACCRUALS (Tables)", "shortName": "OTHER PAYABLES AND ACCRUALS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "legn:DisclosureOfDetailedInformationAboutOtherPayablesAndAccrualsExplanatoryTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "legn-20260630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "legn:DisclosureOfDetailedInformationAboutOtherPayablesAndAccrualsExplanatoryTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "legn-20260630.htm", "first": true, "unique": true } }, "R29": { "role": "http://legendbiotech.com/role/REVENUESummaryofAnalysisofRevenueDetails", "longName": "9955520 - Disclosure - REVENUE - Summary of Analysis of Revenue (Details)", "shortName": "REVENUE - Summary of Analysis of Revenue (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "c-2", "name": "ifrs-full:OtherRevenue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20260630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-2", "name": "ifrs-full:OtherRevenue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20260630.htm", "first": true, "unique": true } }, "R30": { "role": "http://legendbiotech.com/role/REVENUESummaryofRevenueDetails", "longName": "9955521 - Disclosure - REVENUE - Summary of Revenue (Details)", "shortName": "REVENUE - Summary of Revenue (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "c-2", "name": "legn:RevenueFromLicensingOfIntellectualPropertyAndOther", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20260630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-49", "name": "legn:RevenueFromLicensingOfIntellectualPropertyAndOther", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfGeographicalAreasExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20260630.htm", "unique": true } }, "R31": { "role": "http://legendbiotech.com/role/REVENUEAnalysisofTimingofTransferofGoodsorServicesDetails", "longName": "9955522 - Disclosure - REVENUE - Analysis of Timing of Transfer of Goods or Services (Details)", "shortName": "REVENUE - Analysis of Timing of Transfer of Goods or Services (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "c-2", "name": "ifrs-full:RevenueFromContractsWithCustomers", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "legn:DisclosureOfTimingOfTransferOfGoodsOrServicesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20260630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-57", "name": "ifrs-full:RevenueFromContractsWithCustomers", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "legn:DisclosureOfTimingOfTransferOfGoodsOrServicesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20260630.htm", "unique": true } }, "R32": { "role": "http://legendbiotech.com/role/OTHEREXPENSENETDetails", "longName": "9955523 - Disclosure - OTHER EXPENSE, NET (Details)", "shortName": "OTHER EXPENSE, NET (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "c-2", "name": "ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "legn:DisclosureOfDetailedInformationAboutOtherIncomeExpenseTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "legn-20260630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-2", "name": "ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "legn:DisclosureOfDetailedInformationAboutOtherIncomeExpenseTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "legn-20260630.htm", "first": true, "unique": true } }, "R33": { "role": "http://legendbiotech.com/role/EARNINGSLOSSPERSHARESummaryofCalculationsofBasicandDilutedEarningsLossperShareDetails", "longName": "9955524 - Disclosure - EARNINGS (LOSS) PER SHARE - Summary of Calculations of Basic and Diluted Earnings (Loss) per Share (Details)", "shortName": "EARNINGS (LOSS) PER SHARE - Summary of Calculations of Basic and Diluted Earnings (Loss) per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "c-2", "name": "ifrs-full:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:EarningsPerShareExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20260630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-2", "name": "ifrs-full:WeightedAverageShares", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:EarningsPerShareExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20260630.htm", "unique": true } }, "R34": { "role": "http://legendbiotech.com/role/LEASESAdditionalInformationDetails", "longName": "9955525 - Disclosure - LEASES - Additional Information (Details)", "shortName": "LEASES - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "c-5", "name": "ifrs-full:CurrentPrepaymentsAndOtherCurrentAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20260630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-71", "name": "legn:LeaseCommitmentPercentageOfFutureLeasePaymentsExpectedUnderProfitSharingAgreement", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20260630.htm", "unique": true } }, "R35": { "role": "http://legendbiotech.com/role/LEASESSummaryofCarryingAmountsofTheRightofuseAssetsandMovementsDetails", "longName": "9955526 - Disclosure - LEASES - Summary of Carrying Amounts of The Right-of-use Assets and Movements (Details)", "shortName": "LEASES - Summary of Carrying Amounts of The Right-of-use Assets and Movements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "c-6", "name": "ifrs-full:RightofuseAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20260630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:AdditionsToRightofuseAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20260630.htm", "unique": true } }, "R36": { "role": "http://legendbiotech.com/role/LEASESSummaryofLeaseLiabilitiesMeasuredatPresentValueofLeasePaymentstobeMadeOverLeaseTermDetails", "longName": "9955527 - Disclosure - LEASES - Summary of Lease Liabilities Measured at Present Value of Lease Payments to be Made Over Lease Term (Details)", "shortName": "LEASES - Summary of Lease Liabilities Measured at Present Value of Lease Payments to be Made Over Lease Term (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "c-5", "name": "ifrs-full:CurrentLeaseLiabilities", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20260630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-69", "name": "legn:IncreaseInLeaseLiabilities", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20260630.htm", "unique": true } }, "R37": { "role": "http://legendbiotech.com/role/COLLABORATIONINVENTORIESNETSummaryofInventoriesDetails", "longName": "9955528 - Disclosure - COLLABORATION INVENTORIES, NET - Summary of Inventories (Details)", "shortName": "COLLABORATION INVENTORIES, NET - Summary of Inventories (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "c-5", "name": "ifrs-full:RawMaterials", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "legn:DisclosureOfDetailedInformationAboutInventoriesExplanatoryTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20260630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "ifrs-full:RawMaterials", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "legn:DisclosureOfDetailedInformationAboutInventoriesExplanatoryTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20260630.htm", "first": true, "unique": true } }, "R38": { "role": "http://legendbiotech.com/role/COLLABORATIONINVENTORIESNETAdditionalInformationDetails", "longName": "9955529 - Disclosure - COLLABORATION INVENTORIES, NET - Additional Information (Details)", "shortName": "COLLABORATION INVENTORIES, NET - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "c-5", "name": "legn:InventoryReserve", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20260630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "legn:InventoryReserve", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20260630.htm", "first": true, "unique": true } }, "R39": { "role": "http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSDetails", "longName": "9955530 - Disclosure - PREPAYMENTS, OTHER RECEIVABLES AND OTHER ASSETS (Details)", "shortName": "PREPAYMENTS, OTHER RECEIVABLES AND OTHER ASSETS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "c-72", "name": "legn:OtherCollaborationReceivables", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "legn:DisclosureOfDetailedInformationAboutPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20260630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-72", "name": "legn:OtherCollaborationReceivables", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "legn:DisclosureOfDetailedInformationAboutPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20260630.htm", "first": true, "unique": true } }, "R40": { "role": "http://legendbiotech.com/role/INCOMETAXDetails", "longName": "9955531 - Disclosure - INCOME TAX (Details)", "shortName": "INCOME TAX (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "c-2", "name": "ifrs-full:IncomeTaxExpenseContinuingOperations", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20260630.htm", "first": true }, "uniqueAnchor": null }, "R41": { "role": "http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGSummaryofInterestBearingLoansandBorrowingsDetails", "longName": "9955532 - Disclosure - COLLABORATION INTEREST-BEARING ADVANCED FUNDING - Summary of Interest-Bearing Loans and Borrowings (Details)", "shortName": "COLLABORATION INTEREST-BEARING ADVANCED FUNDING - Summary of Interest-Bearing Loans and Borrowings (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "c-74", "name": "ifrs-full:BorrowingsInterestRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "4", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "legn-20260630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-74", "name": "ifrs-full:BorrowingsInterestRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "4", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "legn-20260630.htm", "first": true, "unique": true } }, "R42": { "role": "http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGAdditionalInformationDetails", "longName": "9955533 - Disclosure - COLLABORATION INTEREST-BEARING ADVANCED FUNDING - Additional Information (Details)", "shortName": "COLLABORATION INTEREST-BEARING ADVANCED FUNDING - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c-1", "name": "legn:InterestBearingBorrowingsFundingAdvancesIncreaseDecrease", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20260630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "legn:InterestBearingBorrowingsFundingAdvancesIncreaseDecrease", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20260630.htm", "first": true, "unique": true } }, "R43": { "role": "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofSharesDetails", "longName": "9955534 - Disclosure - SHARE CAPITAL AND SHARE PREMIUM - Summary of Shares (Details)", "shortName": "SHARE CAPITAL AND SHARE PREMIUM - Summary of Shares (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c-5", "name": "ifrs-full:IssuedCapital", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20260630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-76", "name": "ifrs-full:NumberOfSharesAuthorised", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "td", "tr", "table", "div", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20260630.htm", "unique": true } }, "R44": { "role": "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofMovementsintheCompanysShareCapitalandSharePremiumDetails", "longName": "9955535 - Disclosure - SHARE CAPITAL AND SHARE PREMIUM - Summary of Movements in the Company's Share Capital and Share Premium (Details)", "shortName": "SHARE CAPITAL AND SHARE PREMIUM - Summary of Movements in the Company's Share Capital and Share Premium (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c-6", "name": "legn:ShareCapitalAndSharePremium", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "legn:DisclosureOfMovementsInCompanyShareCapitalAndSharePremiumExplanatoryTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20260630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "legn:ShareCapitalAndSharePremium", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "legn:DisclosureOfMovementsInCompanyShareCapitalAndSharePremiumExplanatoryTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20260630.htm", "first": true, "unique": true } }, "R45": { "role": "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMAdditionalInformationDetails", "longName": "9955536 - Disclosure - SHARE CAPITAL AND SHARE PREMIUM - Additional Information (Details)", "shortName": "SHARE CAPITAL AND SHARE PREMIUM - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c-82", "name": "legn:StockIssuedDuringPeriodSharesNewIssues", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20260630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-82", "name": "legn:StockIssuedDuringPeriodSharesNewIssues", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20260630.htm", "first": true, "unique": true } }, "R46": { "role": "http://legendbiotech.com/role/OTHERPAYABLESANDACCRUALSDetails", "longName": "9955537 - Disclosure - OTHER PAYABLES AND ACCRUALS (Details)", "shortName": "OTHER PAYABLES AND ACCRUALS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c-5", "name": "legn:AccruedPayrollAndEmployeeRelatedExpenses", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "legn:DisclosureOfDetailedInformationAboutOtherPayablesAndAccrualsExplanatoryTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "legn-20260630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "legn:AccruedPayrollAndEmployeeRelatedExpenses", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "legn:DisclosureOfDetailedInformationAboutOtherPayablesAndAccrualsExplanatoryTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "legn-20260630.htm", "first": true, "unique": true } } }, "tag": { "legn_A110InterestBearingLoansMember": { "xbrltype": "domainItemType", "nsuri": "http://legendbiotech.com/20260630", "localname": "A110InterestBearingLoansMember", "presentation": [ "http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGAdditionalInformationDetails", "http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGSummaryofInterestBearingLoansandBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest Bearing Loans", "label": "11.0% Interest Bearing Loans [Member]", "documentation": "11.0% Interest Bearing Loans" } } }, "auth_ref": [] }, "legn_AccruedExpensesAndOtherPayables": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20260630", "localname": "AccruedExpensesAndOtherPayables", "crdr": "credit", "calculation": { "http://legendbiotech.com/role/OTHERPAYABLESANDACCRUALSDetails": { "parentTag": "legn_OtherPayablesAndAccrualsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://legendbiotech.com/role/OTHERPAYABLESANDACCRUALSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses and other payables", "label": "Accrued Expenses And Other Payables", "documentation": "Accrued expense." } } }, "auth_ref": [] }, "legn_AccruedPayrollAndEmployeeRelatedExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20260630", "localname": "AccruedPayrollAndEmployeeRelatedExpenses", "crdr": "credit", "calculation": { "http://legendbiotech.com/role/OTHERPAYABLESANDACCRUALSDetails": { "parentTag": "legn_OtherPayablesAndAccrualsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://legendbiotech.com/role/OTHERPAYABLESANDACCRUALSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued payroll and employee-related expenses", "label": "Accrued Payroll And Employee-Related Expenses", "documentation": "Accrued Payroll And Employee-Related Expenses" } } }, "auth_ref": [] }, "ifrs-full_AdditionsToRightofuseAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdditionsToRightofuseAssets", "crdr": "debit", "presentation": [ "http://legendbiotech.com/role/LEASESSummaryofCarryingAmountsofTheRightofuseAssetsandMovementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additions", "label": "Additions to right-of-use assets" } }, "en": { "role": { "documentation": "The amount of additions to right-of-use assets. [Refer: Right-of-use assets]" } } }, "auth_ref": [ "r52", "r79" ] }, "ifrs-full_AdjustedWeightedAverageShares": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustedWeightedAverageShares", "presentation": [ "http://legendbiotech.com/role/EARNINGSLOSSPERSHARESummaryofCalculationsofBasicandDilutedEarningsLossperShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted (in shares)", "label": "Weighted average number of ordinary shares used in calculating diluted earnings per share" } }, "en": { "role": { "documentation": "The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]" } } }, "auth_ref": [ "r15" ] }, "ifrs-full_AdjustmentsForDecreaseIncreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForDecreaseIncreaseInInventories", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Increase in collaboration inventories", "label": "Adjustments for decrease (increase) in inventories" } } }, "auth_ref": [ "r176" ] }, "legn_AdjustmentsForDecreaseIncreaseInPrepaymentsOtherReceivableOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20260630", "localname": "AdjustmentsForDecreaseIncreaseInPrepaymentsOtherReceivableOtherAssets", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Increase in prepayments, other receivables and other assets", "label": "Adjustments For Decrease Increase In Prepayments Other Receivable Other Assets", "documentation": "Adjustments for decrease increase in prepayments other receivable other assets." } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForDecreaseIncreaseInTradeAccountReceivable", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Decrease/(increase) in trade receivables", "label": "Adjustments for decrease (increase) in trade accounts receivable" } } }, "auth_ref": [ "r176" ] }, "ifrs-full_AdjustmentsForDepreciationExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForDepreciationExpense", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation of property, plant and equipment", "label": "Adjustments for depreciation expense" } }, "en": { "role": { "documentation": "Adjustments for depreciation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r179" ] }, "legn_AdjustmentsForDepreciationOfRightOfUseAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20260630", "localname": "AdjustmentsForDepreciationOfRightOfUseAssets", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation of right-of-use assets", "label": "Adjustments For Depreciation Of Right Of Use Assets", "documentation": "Adjustments for depreciation of right-of-use assets." } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForFinanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForFinanceCosts", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Finance costs", "label": "Adjustments for finance costs" } } }, "auth_ref": [ "r178" ] }, "ifrs-full_AdjustmentsForFinanceIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForFinanceIncome", "crdr": "credit", "calculation": { "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Finance income", "label": "Adjustments for finance income" } } }, "auth_ref": [ "r179" ] }, "ifrs-full_AdjustmentsForIncreaseDecreaseInContractLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForIncreaseDecreaseInContractLiabilities", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Decrease in contract liabilities", "label": "Adjustments for increase (decrease) in contract liabilities" } }, "en": { "role": { "documentation": "Adjustments for the increase (decrease) in contract liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Contract liabilities; Profit (loss)]" } } }, "auth_ref": [ "r176" ] }, "legn_AdjustmentsForIncreaseDecreaseInOtherAssetsAndLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20260630", "localname": "AdjustmentsForIncreaseDecreaseInOtherAssetsAndLiabilitiesNet", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Other assets and liabilities, net", "label": "Adjustments for Increase (Decrease) In Other Assets and liabilities, Net", "documentation": "Adjustments for Increase (Decrease) In Other Assets and liabilities, Net" } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForIncreaseDecreaseInOtherOperatingPayables", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Decrease in other payables and accruals", "label": "Adjustments for increase (decrease) in other operating payables" } } }, "auth_ref": [ "r176" ] }, "ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "(Decrease)/increase in trade payables", "label": "Adjustments for increase (decrease) in trade and other payables" } }, "en": { "role": { "documentation": "Adjustments for increase (decrease) in trade and other payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other payables; Profit (loss)]" } } }, "auth_ref": [ "r179" ] }, "legn_AdjustmentsForInventoryReserveProvision": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20260630", "localname": "AdjustmentsForInventoryReserveProvision", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Provision for inventory reserve", "label": "Adjustments For Inventory Reserve Provision", "documentation": "Adjustments For Inventory Reserve Provision" } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForReconcileProfitLossAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForReconcileProfitLossAbstract", "presentation": [ "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments for:", "label": "Adjustments to reconcile profit (loss) [abstract]" } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForUnrealisedForeignExchangeLossesGains", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized foreign currency exchange loss", "label": "Adjustments for unrealised foreign exchange losses (gains)" } } }, "auth_ref": [ "r153", "r177" ] }, "ifrs-full_AdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdministrativeExpense", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOMELOSS": { "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOMELOSS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Administrative expenses", "label": "Administrative expenses" } } }, "auth_ref": [ "r10", "r143", "r167" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AmendmentFlag", "presentation": [ "http://legendbiotech.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "legn_ApprovalOfInterimFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://legendbiotech.com/20260630", "localname": "ApprovalOfInterimFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Approval Of Interim Financial Statements [Abstract]", "documentation": "Approval Of Interim Financial Statements" } } }, "auth_ref": [] }, "ifrs-full_Assets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Assets", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL ASSETS", "label": "Assets" } }, "en": { "role": { "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits." } } }, "auth_ref": [ "r41", "r42", "r43", "r67", "r70", "r107", "r108", "r126" ] }, "legn_AuthorisedAbstract": { "xbrltype": "stringItemType", "nsuri": "http://legendbiotech.com/20260630", "localname": "AuthorisedAbstract", "presentation": [ "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Authorized:", "label": "Authorised [Abstract]", "documentation": "Authorised." } } }, "auth_ref": [] }, "legn_AuthorizedShareCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20260630", "localname": "AuthorizedShareCapital", "crdr": "credit", "presentation": [ "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Authorized amount", "label": "Authorized Share Capital", "documentation": "Authorized share capital." } } }, "auth_ref": [] }, "ifrs-full_BasicEarningsLossPerShare": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BasicEarningsLossPerShare", "presentation": [ "http://legendbiotech.com/role/EARNINGSLOSSPERSHARESummaryofCalculationsofBasicandDilutedEarningsLossperShareDetails", "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOMELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "Basic (in dollars per share)", "label": "Basic earnings (loss) per share" } }, "en": { "role": { "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator)." } } }, "auth_ref": [ "r13", "r14" ] }, "ifrs-full_BasicEarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BasicEarningsPerShareAbstract", "lang": { "en-us": { "role": { "terseLabel": "Basic earnings per share [abstract]", "label": "Basic earnings per share [abstract]" } } }, "auth_ref": [] }, "legn_BasisOfPreparationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://legendbiotech.com/20260630", "localname": "BasisOfPreparationAbstract", "lang": { "en-us": { "role": { "label": "Basis of Preparation [Abstract]", "documentation": "Basis of Preparation [Abstract]" } } }, "auth_ref": [] }, "ifrs-full_BorrowingsAdjustmentToInterestRateBasis": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BorrowingsAdjustmentToInterestRateBasis", "presentation": [ "http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest rate margin percentage", "label": "Borrowings, adjustment to interest rate basis" } }, "en": { "role": { "documentation": "The adjustment to the basis (reference rate) used for calculation of the interest rate on borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r182" ] }, "ifrs-full_BorrowingsByNameAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BorrowingsByNameAxis", "presentation": [ "http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGAdditionalInformationDetails", "http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGSummaryofInterestBearingLoansandBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowings by name [axis]", "label": "Borrowings by name [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r182" ] }, "ifrs-full_BorrowingsByNameDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BorrowingsByNameDomain", "presentation": [ "http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGAdditionalInformationDetails", "http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGSummaryofInterestBearingLoansandBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowings by name [domain]", "label": "Borrowings by name [domain]" } }, "en": { "role": { "documentation": "This member stands for all borrowings when disaggregated by name. It also represents the standard value for the 'Borrowings by name' axis if no other member is used. [Refer: Borrowings]" } } }, "auth_ref": [ "r182" ] }, "ifrs-full_BorrowingsInterestRate": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BorrowingsInterestRate", "presentation": [ "http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGSummaryofInterestBearingLoansandBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effective interest rate (%)", "label": "Borrowings, interest rate" } }, "en": { "role": { "documentation": "The interest rate on borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r182" ] }, "ifrs-full_BottomOfRangeMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BottomOfRangeMember", "presentation": [ "http://legendbiotech.com/role/LEASESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Bottom of Range", "label": "Bottom of range [member]" } }, "en": { "role": { "documentation": "This member stands for the bottom of a range." } } }, "auth_ref": [ "r24", "r44", "r57", "r58", "r90", "r156", "r157", "r182" ] }, "ifrs-full_Cash": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Cash", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Cash and bank balances", "label": "Cash" } }, "en": { "role": { "documentation": "The amount of cash on hand and demand deposits. [Refer: Cash on hand]" } } }, "auth_ref": [ "r181" ] }, "ifrs-full_CashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashAndCashEquivalents", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "periodStartLabel": "Cash and cash equivalents at beginning of year", "periodEndLabel": "CASH AND CASH EQUIVALENTS AT END OF PERIOD", "label": "Cash and cash equivalents" } }, "en": { "role": { "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]" } } }, "auth_ref": [ "r25", "r39", "r91", "r124" ] }, "ifrs-full_CashAndCashEquivalentsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashAndCashEquivalentsAbstract", "presentation": [ "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "ANALYSIS OF BALANCES OF CASH AND CASH EQUIVALENTS", "label": "Cash and cash equivalents [abstract]" } } }, "auth_ref": [] }, "legn_CashAndCashEquivalentsAsStatedInStatementOfFinancialPosition": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20260630", "localname": "CashAndCashEquivalentsAsStatedInStatementOfFinancialPosition", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_Cash", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents as stated in the statement of financial position", "label": "Cash And Cash Equivalents As Stated In Statement Of Financial Position", "documentation": "Cash and cash equivalents as stated in statement of financial position." } } }, "auth_ref": [] }, "ifrs-full_CashFlowsFromUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by/(used in) financing activities", "label": "Cash flows from (used in) financing activities" } }, "en": { "role": { "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity, from continuing and discontinued operations." } } }, "auth_ref": [ "r18", "r26" ] }, "ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInFinancingActivitiesAbstract", "presentation": [ "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES", "label": "Cash flows from (used in) financing activities [abstract]" } } }, "auth_ref": [] }, "ifrs-full_CashFlowsFromUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash (used in)/provided by investing activities", "label": "Cash flows from (used in) investing activities" } }, "en": { "role": { "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents, from continuing and discontinued operations." } } }, "auth_ref": [ "r18", "r26" ] }, "ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInInvestingActivitiesAbstract", "presentation": [ "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES", "label": "Cash flows from (used in) investing activities [abstract]" } } }, "auth_ref": [] }, "ifrs-full_CashFlowsFromUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInOperatingActivities", "calculation": { "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in operating activities", "label": "Cash flows from (used in) operating activities" } } }, "auth_ref": [ "r18", "r26" ] }, "ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInOperatingActivitiesAbstract", "presentation": [ "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES", "label": "Cash flows from (used in) operating activities [abstract]" } } }, "auth_ref": [] }, "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "calculation": { "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Cash flows provided by (used in) operations before changes in working capital", "label": "Cash flows from (used in) operations before changes in working capital" } }, "en": { "role": { "documentation": "The cash inflow (outflow) from the entity's operations before changes in working capital." } } }, "auth_ref": [ "r153", "r179" ] }, "ifrs-full_CashOutflowForLeases": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashOutflowForLeases", "crdr": "credit", "presentation": [ "http://legendbiotech.com/role/LEASESSummaryofLeaseLiabilitiesMeasuredatPresentValueofLeasePaymentstobeMadeOverLeaseTermDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Payments", "label": "Cash outflow for leases" } }, "en": { "role": { "documentation": "The cash outflow for leases." } } }, "auth_ref": [ "r51", "r78" ] }, "ifrs-full_ClassesOfFinancialInstrumentsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfFinancialInstrumentsAxis", "presentation": [ "http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of financial instruments [axis]", "label": "Classes of financial instruments [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r60", "r61", "r62", "r63", "r105", "r106" ] }, "ifrs-full_ClassesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfFinancialInstrumentsDomain", "presentation": [ "http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of financial instruments [domain]", "label": "Classes of financial instruments [domain]" } }, "en": { "role": { "documentation": "This member stands for aggregated classes of financial instruments. Financial instruments are contracts that give rise to a financial asset of one entity and a financial liability or equity instrument of another entity. It also represents the standard value for the 'Classes of financial instruments' axis if no other member is used. [Refer: Financial assets; Financial liabilities]" } } }, "auth_ref": [ "r60", "r61", "r62", "r63", "r105", "r106" ] }, "ifrs-full_ClassesOfInventoriesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfInventoriesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Classes of current inventories [abstract]", "label": "Classes of current inventories [abstract]" } } }, "auth_ref": [] }, "ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfPropertyPlantAndEquipmentAxis", "presentation": [ "http://legendbiotech.com/role/LEASESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of property, plant and equipment [axis]", "label": "Classes of property, plant and equipment [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r5", "r97" ] }, "ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfPropertyPlantAndEquipmentDomain", "presentation": [ "http://legendbiotech.com/role/LEASESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of property, plant and equipment [domain]", "label": "Classes of property, plant and equipment [domain]" } }, "en": { "role": { "documentation": "This member stands for the standard value for the 'Classes of property, plant and equipment' axis if no other member is used." } } }, "auth_ref": [ "r5", "r97" ] }, "ifrs-full_ClassesOfShareCapitalAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfShareCapitalAxis", "presentation": [ "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of share capital [axis]", "label": "Classes of share capital [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r85", "r112", "r134" ] }, "ifrs-full_ClassesOfShareCapitalDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfShareCapitalDomain", "presentation": [ "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of share capital [domain]", "label": "Classes of share capital [domain]" } }, "en": { "role": { "documentation": "This member stands for share capital of the entity. It also represents the standard value for the 'Classes of share capital' axis if no other member is used." } } }, "auth_ref": [ "r85", "r112", "r134" ] }, "legn_CollaborationPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20260630", "localname": "CollaborationPayable", "crdr": "credit", "calculation": { "http://legendbiotech.com/role/OTHERPAYABLESANDACCRUALSDetails": { "parentTag": "legn_OtherPayablesAndAccrualsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://legendbiotech.com/role/OTHERPAYABLESANDACCRUALSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaboration payable", "label": "Collaboration Payable", "documentation": "Collaboration Payable" } } }, "auth_ref": [] }, "legn_CollaborationPrepaidLeases": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20260630", "localname": "CollaborationPrepaidLeases", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "Collaboration prepaid leases", "label": "Collaboration Prepaid Leases", "documentation": "Collaboration Prepaid Leases" } } }, "auth_ref": [] }, "legn_CollaborationRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20260630", "localname": "CollaborationRevenue", "crdr": "credit", "calculation": { "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOMELOSS": { "parentTag": "ifrs-full_Revenue", "weight": 1.0, "order": 1.0 }, "http://legendbiotech.com/role/REVENUESummaryofAnalysisofRevenueDetails": { "parentTag": "ifrs-full_RevenueFromContractsWithCustomers", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://legendbiotech.com/role/REVENUESummaryofAnalysisofRevenueDetails", "http://legendbiotech.com/role/REVENUESummaryofRevenueDetails", "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOMELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "Collaboration revenue", "verboseLabel": "Total collaboration revenue", "label": "Collaboration Revenue", "documentation": "Collaboration Revenue" } } }, "auth_ref": [] }, "ifrs-full_ComponentsOfEquityAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ComponentsOfEquityAxis", "presentation": [ "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMAdditionalInformationDetails", "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofMovementsintheCompanysShareCapitalandSharePremiumDetails", "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Components of equity [axis]", "label": "Components of equity [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r120" ] }, "ifrs-full_ComponentsOfEquityDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ComponentsOfEquityDomain", "presentation": [ "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMAdditionalInformationDetails", "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofMovementsintheCompanysShareCapitalandSharePremiumDetails", "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Components of equity [domain]", "label": "Components of equity [domain]" } }, "en": { "role": { "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used." } } }, "auth_ref": [ "r120" ] }, "ifrs-full_ComprehensiveIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ComprehensiveIncome", "crdr": "credit", "calculation": { "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOMELOSS": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY", "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOMELOSS" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL COMPREHENSIVE INCOME (LOSS)", "label": "Comprehensive income" } }, "en": { "role": { "documentation": "The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners." } } }, "auth_ref": [ "r29", "r31", "r36", "r101", "r104", "r116", "r138", "r155" ] }, "legn_CostOfLicenseAndOtherRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20260630", "localname": "CostOfLicenseAndOtherRevenue", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOMELOSS": { "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOMELOSS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Cost of license and other revenue", "label": "Cost Of License And Other Revenue", "documentation": "Cost Of License And Other Revenue" } } }, "auth_ref": [] }, "ifrs-full_CostOfSales": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CostOfSales", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOMELOSS": { "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOMELOSS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Cost of collaboration revenue", "label": "Cost of sales" } } }, "auth_ref": [ "r115", "r143" ] }, "ifrs-full_CounterpartiesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CounterpartiesAxis", "presentation": [ "http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGAdditionalInformationDetails", "http://legendbiotech.com/role/LEASESAdditionalInformationDetails", "http://legendbiotech.com/role/REVENUESummaryofAnalysisofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparties [axis]", "label": "Counterparties [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r64" ] }, "ifrs-full_CounterpartiesDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CounterpartiesDomain", "presentation": [ "http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGAdditionalInformationDetails", "http://legendbiotech.com/role/LEASESAdditionalInformationDetails", "http://legendbiotech.com/role/REVENUESummaryofAnalysisofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparties [domain]", "label": "Counterparties [domain]" } }, "en": { "role": { "documentation": "This member stands for the parties to the transaction other than the entity. It also represents the standard value for the 'Counterparties' axis if no other member is used." } } }, "auth_ref": [ "r64" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "ifrs-full_CurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentAssets", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Current assets" } }, "en": { "role": { "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]" } } }, "auth_ref": [ "r32", "r127", "r155" ] }, "ifrs-full_CurrentAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentAssetsAbstract", "presentation": [ "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "CURRENT ASSETS", "label": "Current assets [abstract]" } } }, "auth_ref": [] }, "ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings", "crdr": "credit", "calculation": { "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "Collaboration interest-bearing advanced funding", "label": "Current borrowings and current portion of non-current borrowings" } }, "en": { "role": { "documentation": "The amount of current borrowings and current portion of non-current borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r188" ] }, "ifrs-full_CurrentContractLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentContractLiabilities", "crdr": "credit", "calculation": { "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "Contract liabilities", "label": "Current contract liabilities" } }, "en": { "role": { "documentation": "The amount of current contract liabilities. [Refer: Contract liabilities]" } } }, "auth_ref": [ "r45" ] }, "ifrs-full_CurrentFinanceLeaseReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentFinanceLeaseReceivables", "crdr": "debit", "presentation": [ "http://legendbiotech.com/role/LEASESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current finance lease receivables", "label": "Current finance lease receivables" } }, "en": { "role": { "documentation": "The amount of current finance lease receivables. [Refer: Finance lease receivables]" } } }, "auth_ref": [ "r188" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://legendbiotech.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "ifrs-full_CurrentLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentLeaseLiabilities", "crdr": "credit", "calculation": { "http://legendbiotech.com/role/LEASESSummaryofLeaseLiabilitiesMeasuredatPresentValueofLeasePaymentstobeMadeOverLeaseTermDetails": { "parentTag": "ifrs-full_LeaseLiabilities", "weight": 1.0, "order": 2.0 }, "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://legendbiotech.com/role/LEASESSummaryofLeaseLiabilitiesMeasuredatPresentValueofLeasePaymentstobeMadeOverLeaseTermDetails", "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "Lease liabilities", "verboseLabel": "Current portion", "label": "Current lease liabilities" } }, "en": { "role": { "documentation": "The amount of current lease liabilities. [Refer: Lease liabilities]" } } }, "auth_ref": [ "r49" ] }, "ifrs-full_CurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentLiabilities", "crdr": "credit", "calculation": { "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Current liabilities" } }, "en": { "role": { "documentation": "The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period." } } }, "auth_ref": [ "r34", "r128", "r155" ] }, "ifrs-full_CurrentLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentLiabilitiesAbstract", "presentation": [ "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "CURRENT LIABILITIES", "label": "Current liabilities [abstract]" } } }, "auth_ref": [] }, "ifrs-full_CurrentLoansReceivedAndCurrentPortionOfNoncurrentLoansReceived": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentLoansReceivedAndCurrentPortionOfNoncurrentLoansReceived", "crdr": "credit", "presentation": [ "http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGSummaryofInterestBearingLoansandBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaboration interest-bearing advanced funding", "label": "Current loans received and current portion of non-current loans received" } }, "en": { "role": { "documentation": "The amount of current loans received and the current portion of non-current loans received. [Refer: Loans received]" } } }, "auth_ref": [ "r187" ] }, "ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentPrepaymentsAndOtherCurrentAssets", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://legendbiotech.com/role/LEASESAdditionalInformationDetails", "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "Prepayments, other receivables and other assets", "label": "Current prepayments and other current assets" } }, "en": { "role": { "documentation": "The amount of current prepayments and other current assets. [Refer: Other current assets; Current prepayments]" } } }, "auth_ref": [ "r188" ] }, "ifrs-full_CurrentTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentTaxLiabilities", "crdr": "credit", "calculation": { "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "Tax payable", "label": "Current tax liabilities" } }, "en": { "role": { "documentation": "The amount of current tax for current and prior periods to the extent unpaid. Current tax is the amount of income taxes payable (recoverable) in respect of the taxable profit (tax loss) for a period." } } }, "auth_ref": [ "r125" ] }, "ifrs-full_CurrentTradeReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentTradeReceivables", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "Trade receivables", "label": "Current trade receivables" } }, "en": { "role": { "documentation": "The amount of current trade receivables. [Refer: Trade receivables]" } } }, "auth_ref": [ "r163", "r169", "r170" ] }, "ifrs-full_DepreciationRightofuseAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DepreciationRightofuseAssets", "presentation": [ "http://legendbiotech.com/role/LEASESSummaryofCarryingAmountsofTheRightofuseAssetsandMovementsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Depreciation of right-of-use assets", "label": "Depreciation, right-of-use assets" } } }, "auth_ref": [ "r50", "r77" ] }, "ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations", "presentation": [ "http://legendbiotech.com/role/NEWSTANDARDSINTERPRETATIONSANDAMENDMENTSADOPTEDBYTHECOMPANY" ], "lang": { "en-us": { "role": { "terseLabel": "NEW STANDARDS, INTERPRETATIONS AND AMENDMENTS ADOPTED BY THE COMPANY", "label": "Disclosure of expected impact of initial application of new standards or interpretations [text block]" } } }, "auth_ref": [ "r27", "r92" ] }, "ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsAbstract", "lang": { "en-us": { "role": { "label": "Disclosure of expected impact of initial application of new standards or interpretations [abstract]" } } }, "auth_ref": [] }, "ifrs-full_DilutedEarningsLossPerShare": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DilutedEarningsLossPerShare", "presentation": [ "http://legendbiotech.com/role/EARNINGSLOSSPERSHARESummaryofCalculationsofBasicandDilutedEarningsLossperShareDetails", "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOMELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted (in dollars per share)", "label": "Diluted earnings (loss) per share" } }, "en": { "role": { "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]" } } }, "auth_ref": [ "r13", "r14" ] }, "ifrs-full_DisclosureOfAuthorisationOfFinancialStatementsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfAuthorisationOfFinancialStatementsExplanatory", "presentation": [ "http://legendbiotech.com/role/APPROVALOFTHEINTERIMCONDENSEDCONSOLIDATEDFINANCIALSTATEMENTS" ], "lang": { "en-us": { "role": { "terseLabel": "APPROVAL OF THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS", "label": "Disclosure of authorisation of financial statements [text block]" } }, "en": { "role": { "documentation": "The disclosure of the authorisation of financial statements for issue." } } }, "auth_ref": [ "r183" ] }, "ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory", "presentation": [ "http://legendbiotech.com/role/BASISOFPREPARATION" ], "lang": { "en-us": { "role": { "terseLabel": "BASIS OF PREPARATION", "label": "Disclosure of basis of preparation of financial statements [text block]" } } }, "auth_ref": [ "r183" ] }, "ifrs-full_DisclosureOfBorrowingsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfBorrowingsExplanatory", "presentation": [ "http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDING" ], "lang": { "en-us": { "role": { "terseLabel": "COLLABORATION INTEREST-BEARING ADVANCED FUNDING", "label": "Disclosure of borrowings [text block]" } }, "en": { "role": { "documentation": "The disclosure of borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r183" ] }, "ifrs-full_DisclosureOfClassesOfShareCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfClassesOfShareCapitalAbstract", "lang": { "en-us": { "role": { "label": "Disclosure of classes of share capital [abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfClassesOfShareCapitalExplanatory", "presentation": [ "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUM" ], "lang": { "en-us": { "role": { "terseLabel": "SHARE CAPITAL AND SHARE PREMIUM", "label": "Disclosure of classes of share capital [text block]" } }, "en": { "role": { "documentation": "The disclosure of classes of share capital. [Refer: Classes of share capital [domain]]" } } }, "auth_ref": [ "r85", "r112", "r134" ] }, "ifrs-full_DisclosureOfClassesOfShareCapitalLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfClassesOfShareCapitalLineItems", "presentation": [ "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMAdditionalInformationDetails", "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofMovementsintheCompanysShareCapitalandSharePremiumDetails", "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Classes Of Share Capital [Line Items]", "label": "Disclosure of classes of share capital [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfClassesOfShareCapitalTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfClassesOfShareCapitalTable", "presentation": [ "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMAdditionalInformationDetails", "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofMovementsintheCompanysShareCapitalandSharePremiumDetails", "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Classes Of Share Capital [Table]", "label": "Disclosure of classes of share capital [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to classes of share capital." } } }, "auth_ref": [ "r85", "r112", "r134" ] }, "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDetailedInformationAboutBorrowingsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Disclosure of detailed information about borrowings [abstract]", "label": "Disclosure of detailed information about borrowings [abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDetailedInformationAboutBorrowingsExplanatory", "presentation": [ "http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Interest-Bearing Loans and Borrowings", "label": "Disclosure of detailed information about borrowings [text block]" } }, "en": { "role": { "documentation": "The disclosure of detailed information about borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r182" ] }, "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDetailedInformationAboutBorrowingsLineItems", "presentation": [ "http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGAdditionalInformationDetails", "http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGSummaryofInterestBearingLoansandBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Detailed Information About Borrowings [Line Items]", "label": "Disclosure of detailed information about borrowings [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDetailedInformationAboutBorrowingsTable", "presentation": [ "http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGAdditionalInformationDetails", "http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGSummaryofInterestBearingLoansandBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Detailed Information About Borrowings [Table]", "label": "Disclosure of detailed information about borrowings [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to details of borrowings." } } }, "auth_ref": [ "r182" ] }, "legn_DisclosureOfDetailedInformationAboutInventoriesExplanatoryTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://legendbiotech.com/20260630", "localname": "DisclosureOfDetailedInformationAboutInventoriesExplanatoryTableTextBlock", "presentation": [ "http://legendbiotech.com/role/COLLABORATIONINVENTORIESNETTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Inventories", "label": "Disclosure Of Detailed Information About Inventories Explanatory [Table Text Block]", "documentation": "The disclosure of detailed information about inventories." } } }, "auth_ref": [] }, "legn_DisclosureOfDetailedInformationAboutLeaseLiabilitiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://legendbiotech.com/20260630", "localname": "DisclosureOfDetailedInformationAboutLeaseLiabilitiesLineItems", "presentation": [ "http://legendbiotech.com/role/LEASESSummaryofLeaseLiabilitiesMeasuredatPresentValueofLeasePaymentstobeMadeOverLeaseTermDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Detailed Information About Lease Liabilities [Line Items]", "label": "Disclosure Of Detailed Information About Lease Liabilities [Line Items]", "documentation": "Disclosure of detailed information about lease liabilities." } } }, "auth_ref": [] }, "legn_DisclosureOfDetailedInformationAboutLeaseLiabilitiesTable": { "xbrltype": "stringItemType", "nsuri": "http://legendbiotech.com/20260630", "localname": "DisclosureOfDetailedInformationAboutLeaseLiabilitiesTable", "presentation": [ "http://legendbiotech.com/role/LEASESSummaryofLeaseLiabilitiesMeasuredatPresentValueofLeasePaymentstobeMadeOverLeaseTermDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Detailed Information About Lease Liabilities [Table]", "label": "Disclosure Of Detailed Information About Lease Liabilities [Table]", "documentation": "Disclosure of detailed information about lease liabilities." } } }, "auth_ref": [] }, "legn_DisclosureOfDetailedInformationAboutOtherIncomeExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://legendbiotech.com/20260630", "localname": "DisclosureOfDetailedInformationAboutOtherIncomeExpenseTableTextBlock", "presentation": [ "http://legendbiotech.com/role/OTHEREXPENSENETTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Total Other Income and Expense", "label": "Disclosure Of Detailed Information About Other Income (Expense) [Table Text Block]", "documentation": "Disclosure Of Detailed Information About Other Income (Expense)" } } }, "auth_ref": [] }, "legn_DisclosureOfDetailedInformationAboutOtherPayablesAndAccrualsExplanatoryTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://legendbiotech.com/20260630", "localname": "DisclosureOfDetailedInformationAboutOtherPayablesAndAccrualsExplanatoryTableTextBlock", "presentation": [ "http://legendbiotech.com/role/OTHERPAYABLESANDACCRUALSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Other Payables and Accruals", "label": "Disclosure Of Detailed Information About Other Payables And Accruals Explanatory [Table Text Block]", "documentation": "Disclosure of detailed information about other payables and accruals." } } }, "auth_ref": [] }, "legn_DisclosureOfDetailedInformationAboutPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://legendbiotech.com/20260630", "localname": "DisclosureOfDetailedInformationAboutPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTableTextBlock", "presentation": [ "http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Prepayments, Other Receivables and Other Assets", "label": "Disclosure Of Detailed Information About Prepayments Other Receivables And Other Assets Explanatory [Table Text Block]", "documentation": "Disclosure of detailed information about prepayments, other receivables and other assets." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract", "lang": { "en-us": { "role": { "terseLabel": "Disclosure of disaggregation of revenue from contracts with customers [abstract]", "label": "Disclosure of disaggregation of revenue from contracts with customers [abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory", "presentation": [ "http://legendbiotech.com/role/REVENUETables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Analysis of Revenue", "label": "Disclosure of disaggregation of revenue from contracts with customers [text block]" } } }, "auth_ref": [ "r47", "r76" ] }, "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems", "presentation": [ "http://legendbiotech.com/role/REVENUEAnalysisofTimingofTransferofGoodsorServicesDetails", "http://legendbiotech.com/role/REVENUESummaryofAnalysisofRevenueDetails", "http://legendbiotech.com/role/REVENUESummaryofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of disaggregation of revenue from contracts with customers [line items]", "label": "Disclosure of disaggregation of revenue from contracts with customers [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable", "presentation": [ "http://legendbiotech.com/role/REVENUEAnalysisofTimingofTransferofGoodsorServicesDetails", "http://legendbiotech.com/role/REVENUESummaryofAnalysisofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Table]", "label": "Disclosure of disaggregation of revenue from contracts with customers [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to the disaggregation of revenue from contracts with customers." } } }, "auth_ref": [ "r47", "r76" ] }, "ifrs-full_DisclosureOfEarningsPerShareExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfEarningsPerShareExplanatory", "presentation": [ "http://legendbiotech.com/role/EARNINGSLOSSPERSHARE" ], "lang": { "en-us": { "role": { "terseLabel": "EARNINGS (LOSS) PER SHARE", "label": "Disclosure of earnings per share [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r16" ] }, "ifrs-full_DisclosureOfGeographicalAreasExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfGeographicalAreasExplanatory", "presentation": [ "http://legendbiotech.com/role/REVENUETables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Revenue by Geographic Area", "label": "Disclosure of geographical areas [text block]" } }, "en": { "role": { "documentation": "The disclosure of geographical information." } } }, "auth_ref": [ "r74" ] }, "ifrs-full_DisclosureOfIncomeTaxExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfIncomeTaxExplanatory", "presentation": [ "http://legendbiotech.com/role/INCOMETAX" ], "lang": { "en-us": { "role": { "terseLabel": "INCOME TAX", "label": "Disclosure of income tax [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for income taxes." } } }, "auth_ref": [ "r3" ] }, "ifrs-full_DisclosureOfInventoriesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfInventoriesExplanatory", "presentation": [ "http://legendbiotech.com/role/COLLABORATIONINVENTORIESNET" ], "lang": { "en-us": { "role": { "terseLabel": "COLLABORATION INVENTORIES, NET", "label": "Disclosure of inventories [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for inventories." } } }, "auth_ref": [ "r7" ] }, "ifrs-full_DisclosureOfLeasesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfLeasesExplanatory", "presentation": [ "http://legendbiotech.com/role/LEASES" ], "lang": { "en-us": { "role": { "terseLabel": "LEASES", "label": "Disclosure of leases [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for leases." } } }, "auth_ref": [ "r55", "r56" ] }, "legn_DisclosureOfMovementsInCompanyShareCapitalAndSharePremiumExplanatoryTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://legendbiotech.com/20260630", "localname": "DisclosureOfMovementsInCompanyShareCapitalAndSharePremiumExplanatoryTableTextBlock", "presentation": [ "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Movements in the Company's Share Capital and Share Premium", "label": "Disclosure Of Movements In Company Share Capital And Share Premium Explanatory [Table Text Block]", "documentation": "Disclosure of movements in the company's share capital and share premium explanatory." } } }, "auth_ref": [] }, "legn_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://legendbiotech.com/20260630", "localname": "DisclosureOfNotesAndOtherExplanatoryInformationExplanatory", "presentation": [ "http://legendbiotech.com/role/CORPORATEINFORMATION" ], "lang": { "en-us": { "role": { "terseLabel": "CORPORATE INFORMATION", "label": "Disclosure of notes and other explanatory information [text block]", "documentation": "The disclosure of notes and other explanatory information as part of a complete set of financial statements." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfOperatingSegmentsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfOperatingSegmentsTable", "presentation": [ "http://legendbiotech.com/role/REVENUESummaryofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of operating segments [table]", "label": "Disclosure of operating segments [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to operating segments." } } }, "auth_ref": [ "r67" ] }, "legn_DisclosureOfOtherIncomeAndExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://legendbiotech.com/20260630", "localname": "DisclosureOfOtherIncomeAndExpenseAbstract", "lang": { "en-us": { "role": { "label": "Disclosure of Other Income and Expense [Abstract]", "documentation": "Disclosure of Other Income and Gains" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfOtherOperatingIncomeExpenseExplanatory", "presentation": [ "http://legendbiotech.com/role/OTHEREXPENSENET" ], "lang": { "en-us": { "role": { "terseLabel": "OTHER EXPENSE, NET", "label": "Disclosure of other operating income (expense) [text block]" } } }, "auth_ref": [ "r183" ] }, "legn_DisclosureOfOtherPayablesAndAccrualsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://legendbiotech.com/20260630", "localname": "DisclosureOfOtherPayablesAndAccrualsAbstract", "lang": { "en-us": { "role": { "label": "Disclosure Of Other Payables And Accruals [Abstract]", "documentation": "Disclosure of other payables and accruals." } } }, "auth_ref": [] }, "legn_DisclosureOfOtherPayablesAndAccrualsExplanatoryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://legendbiotech.com/20260630", "localname": "DisclosureOfOtherPayablesAndAccrualsExplanatoryTextBlock", "presentation": [ "http://legendbiotech.com/role/OTHERPAYABLESANDACCRUALS" ], "lang": { "en-us": { "role": { "terseLabel": "OTHER PAYABLES AND ACCRUALS", "label": "Disclosure Of Other Payables And Accruals Explanatory [Text Block]", "documentation": "Disclosure of other payables and accruals." } } }, "auth_ref": [] }, "legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://legendbiotech.com/20260630", "localname": "DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsAbstract", "lang": { "en-us": { "role": { "label": "Disclosure Of Prepayments Other Receivables And Other Assets [Abstract]", "documentation": "Disclosure of prepayments, other receivables and other assets." } } }, "auth_ref": [] }, "legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://legendbiotech.com/20260630", "localname": "DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTextBlock", "presentation": [ "http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETS" ], "lang": { "en-us": { "role": { "terseLabel": "PREPAYMENTS, OTHER RECEIVABLES AND OTHER ASSETS", "label": "Disclosure Of Prepayments Other Receivables And Other Assets Explanatory [Text Block]", "documentation": "Disclosure of prepayments, other receivables and other assets." } } }, "auth_ref": [] }, "legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://legendbiotech.com/20260630", "localname": "DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsLineItems", "presentation": [ "http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Prepayments Other Receivables And Other Assets [Line Items]", "label": "Disclosure Of Prepayments Other Receivables And Other Assets [Line Items]", "documentation": "Disclosure of prepayments, other receivables and other assets." } } }, "auth_ref": [] }, "legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://legendbiotech.com/20260630", "localname": "DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsTable", "presentation": [ "http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Prepayments Other Receivables And Other Assets [Table]", "label": "Disclosure Of Prepayments Other Receivables And Other Assets [Table]", "documentation": "Disclosure of prepayments, other receivables and other assets." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory", "presentation": [ "http://legendbiotech.com/role/LEASESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Carrying Amounts of The Right-of-use Assets and Movements", "label": "Disclosure of quantitative information about right-of-use assets [text block]" } }, "en": { "role": { "documentation": "The disclosure of quantitative information about right-of-use assets. [Refer: Right-of-use assets]" } } }, "auth_ref": [ "r54", "r81" ] }, "ifrs-full_DisclosureOfRevenueExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfRevenueExplanatory", "presentation": [ "http://legendbiotech.com/role/REVENUE" ], "lang": { "en-us": { "role": { "terseLabel": "REVENUE", "label": "Disclosure of revenue [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for revenue." } } }, "auth_ref": [ "r183" ] }, "ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "presentation": [ "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Shares", "label": "Disclosure of share capital, reserves and other equity interest [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for share capital, reserves and other equity interest." } } }, "auth_ref": [ "r86", "r113", "r135" ] }, "ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfSignificantInvestmentsInSubsidiariesAbstract", "lang": { "en-us": { "role": { "label": "Disclosure of subsidiaries [abstract]" } } }, "auth_ref": [] }, "legn_DisclosureOfTimingOfTransferOfGoodsOrServicesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://legendbiotech.com/20260630", "localname": "DisclosureOfTimingOfTransferOfGoodsOrServicesTableTextBlock", "presentation": [ "http://legendbiotech.com/role/REVENUETables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Disclosure of Timing of transfer of Goods or Services", "label": "Disclosure Of Timing Of Transfer Of Goods Or Services [Table Text Block]", "documentation": "Disclosure Of Timing Of Transfer Of Goods Or Services" } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://legendbiotech.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://legendbiotech.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentPeriodEndDate", "presentation": [ "http://legendbiotech.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentType", "presentation": [ "http://legendbiotech.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "ifrs-full_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EarningsPerShareAbstract", "presentation": [ "http://legendbiotech.com/role/EARNINGSLOSSPERSHARESummaryofCalculationsofBasicandDilutedEarningsLossperShareDetails", "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOMELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "EARNINGS (LOSS) PER SHARE", "verboseLabel": "Earnings (loss) per share:", "label": "Earnings per share [abstract]" } } }, "auth_ref": [] }, "ifrs-full_EarningsPerShareExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EarningsPerShareExplanatory", "presentation": [ "http://legendbiotech.com/role/EARNINGSLOSSPERSHARETables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Calculations of Basic and Diluted Earnings (Loss) per Share", "label": "Earnings per share [text block]" } }, "en": { "role": { "documentation": "The disclosure of earnings per share." } } }, "auth_ref": [ "r13" ] }, "ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EffectOfExchangeRateChangesOnCashAndCashEquivalents", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of foreign exchange rate changes on cash and cash equivalents", "label": "Effect of exchange rate changes on cash and cash equivalents" } }, "en": { "role": { "documentation": "The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]" } } }, "auth_ref": [ "r20", "r21" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityCentralIndexKey", "presentation": [ "http://legendbiotech.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r173" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityRegistrantName", "presentation": [ "http://legendbiotech.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r173" ] }, "ifrs-full_Equity": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Equity", "crdr": "credit", "calculation": { "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY", "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "totalLabel": "Total equity", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Equity" } }, "en": { "role": { "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities." } } }, "auth_ref": [ "r28", "r30", "r41", "r42", "r43", "r100", "r103", "r107", "r108", "r114", "r126", "r130" ] }, "ifrs-full_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EquityAbstract", "presentation": [ "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "EQUITY", "label": "Equity [abstract]" } } }, "auth_ref": [] }, "ifrs-full_EquityAndLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EquityAndLiabilities", "crdr": "credit", "calculation": { "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY", "label": "Equity and liabilities" } }, "en": { "role": { "documentation": "The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]" } } }, "auth_ref": [ "r126" ] }, "ifrs-full_ExchangeDifferencesOnTranslationAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ExchangeDifferencesOnTranslationAbstract", "presentation": [ "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOMELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "OTHER COMPREHENSIVE INCOME (LOSS)", "label": "Exchange differences on translation [abstract]" } } }, "auth_ref": [] }, "legn_ExerciseOfShareOption": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20260630", "localname": "ExerciseOfShareOption", "crdr": "credit", "presentation": [ "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofMovementsintheCompanysShareCapitalandSharePremiumDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise of share options", "label": "Exercise Of Share Option", "documentation": "Exercise of share option." } } }, "auth_ref": [] }, "legn_ExerciseOfShareOptionNumberOfSharesInIssue": { "xbrltype": "sharesItemType", "nsuri": "http://legendbiotech.com/20260630", "localname": "ExerciseOfShareOptionNumberOfSharesInIssue", "presentation": [ "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofMovementsintheCompanysShareCapitalandSharePremiumDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise of share option (in shares)", "label": "Exercise Of Share Option Number Of Shares In Issue", "documentation": "Exercise of share option number of shares in issue." } } }, "auth_ref": [] }, "ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ExpenseFromSharebasedPaymentTransactionsWithEmployees", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation expense", "label": "Expense from share-based payment transactions with employees" } } }, "auth_ref": [ "r187" ] }, "ifrs-full_FinanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinanceCosts", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOMELOSS": { "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOMELOSS" ], "lang": { "en-us": { "role": { "negatedNetLabel": "Finance costs", "label": "Finance costs" } } }, "auth_ref": [ "r140" ] }, "ifrs-full_FinanceIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinanceIncome", "crdr": "credit", "calculation": { "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOMELOSS": { "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOMELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "Finance income", "label": "Finance income" } } }, "auth_ref": [ "r192" ] }, "ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinanceIncomeReceivedClassifiedAsOperatingActivities", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Interest income received", "label": "Finance income received, classified as operating activities" } } }, "auth_ref": [ "r180" ] }, "ifrs-full_FinanceLeaseReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinanceLeaseReceivables", "crdr": "debit", "presentation": [ "http://legendbiotech.com/role/LEASESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "VAT recoverable", "label": "Finance lease receivables" } }, "en": { "role": { "documentation": "The amount of receivables related to finance leases." } } }, "auth_ref": [ "r188" ] }, "ifrs-full_FinishedGoods": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinishedGoods", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/COLLABORATIONINVENTORIESNETSummaryofInventoriesDetails": { "parentTag": "ifrs-full_Inventories", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://legendbiotech.com/role/COLLABORATIONINVENTORIESNETSummaryofInventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finished goods", "label": "Current finished goods" } }, "en": { "role": { "documentation": "A classification of current inventory representing the amount of goods that have completed the production process and are held for sale in the ordinary course of business. [Refer: Inventories]" } } }, "auth_ref": [ "r164", "r171", "r174" ] }, "ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss", "crdr": "credit", "calculation": { "http://legendbiotech.com/role/OTHEREXPENSENETDetails": { "parentTag": "ifrs-full_OtherGainsLosses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://legendbiotech.com/role/OTHEREXPENSENETDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Foreign currency exchange loss, net", "label": "Foreign exchange gain (loss)" } }, "en": { "role": { "documentation": "The amount of exchange differences recognised in profit or loss that arise from foreign currency transactions, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: At fair value [member]; Classes of financial instruments [domain]]" } } }, "auth_ref": [ "r8", "r98", "r121" ] }, "ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GoodsOrServicesTransferredAtPointInTimeMember", "presentation": [ "http://legendbiotech.com/role/REVENUEAnalysisofTimingofTransferofGoodsorServicesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue at a point in time", "label": "Goods or services transferred at point in time [member]" } }, "en": { "role": { "documentation": "This member stands for goods or services transferred to customers at a point in time. [Refer: Performance obligations satisfied at point in time [member]]" } } }, "auth_ref": [ "r158", "r162" ] }, "ifrs-full_GoodsOrServicesTransferredOverTimeMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GoodsOrServicesTransferredOverTimeMember", "presentation": [ "http://legendbiotech.com/role/REVENUEAnalysisofTimingofTransferofGoodsorServicesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue over time", "label": "Goods or services transferred over time [member]" } }, "en": { "role": { "documentation": "This member stands for goods or services transferred to customers over time. [Refer: Performance obligations satisfied over time [member]]" } } }, "auth_ref": [ "r158", "r162" ] }, "ifrs-full_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Profit or loss [abstract]" } } }, "auth_ref": [] }, "ifrs-full_IncomeTaxExpenseContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncomeTaxExpenseContinuingOperations", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOMELOSS": { "parentTag": "ifrs-full_ProfitLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://legendbiotech.com/role/INCOMETAXDetails", "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOMELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "Income tax expense", "label": "Tax expense (income)" } } }, "auth_ref": [ "r0", "r1", "r2", "r12", "r40", "r66", "r93", "r94", "r95", "r141" ] }, "ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncomeTaxesPaidRefundClassifiedAsOperatingActivities", "crdr": "credit", "calculation": { "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Income tax paid", "label": "Income taxes paid (refund), classified as operating activities" } }, "en": { "role": { "documentation": "The cash flows from income taxes paid or refunded, classified as operating activities. [Refer: Income taxes paid (refund)]" } } }, "auth_ref": [ "r22", "r146" ] }, "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseInCashAndCashEquivalents", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "NET DECREASE IN CASH AND CASH EQUIVALENTS", "label": "Increase (decrease) in cash and cash equivalents after effect of exchange rate changes" } }, "en": { "role": { "documentation": "The increase (decrease) in cash and cash equivalents after the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]" } } }, "auth_ref": [ "r25", "r91" ] }, "ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseInNumberOfOrdinarySharesIssued", "presentation": [ "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMAdditionalInformationDetails", "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofMovementsintheCompanysShareCapitalandSharePremiumDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of ordinary shares, net of issuance costs (in shares)", "label": "Increase (decrease) in number of ordinary shares issued" } }, "en": { "role": { "documentation": "The increase (decrease) in the number of ordinary shares issued. [Refer: Ordinary shares [member]]" } } }, "auth_ref": [ "r187" ] }, "ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities", "crdr": "credit", "presentation": [ "http://legendbiotech.com/role/LEASESSummaryofLeaseLiabilitiesMeasuredatPresentValueofLeasePaymentstobeMadeOverLeaseTermDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exchange realignment", "label": "Increase (decrease) through effect of changes in foreign exchange rates, liabilities arising from financing activities" } }, "en": { "role": { "documentation": "The increase (decrease) in liabilities arising from financing activities resulting from the effect of changes in foreign exchange rates. [Refer: Liabilities arising from financing activities]" } } }, "auth_ref": [ "r23", "r88" ] }, "legn_IncreaseDecreaseThroughEffectOfExchangeRealignmentInForeignExchangeRate": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20260630", "localname": "IncreaseDecreaseThroughEffectOfExchangeRealignmentInForeignExchangeRate", "crdr": "debit", "presentation": [ "http://legendbiotech.com/role/LEASESSummaryofCarryingAmountsofTheRightofuseAssetsandMovementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exchange realignment", "label": "Increase (Decrease) Through Effect Of Exchange Realignment In Foreign Exchange Rate", "documentation": "Increase (decrease) through effect of exchange realignment in foreign exchange rate." } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseThroughExerciseOfOptions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseThroughExerciseOfOptions", "crdr": "credit", "presentation": [ "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise of share options", "label": "Increase (decrease) through exercise of options, equity" } }, "en": { "role": { "documentation": "The increase (decrease) in equity resulting from the exercise of options." } } }, "auth_ref": [ "r186" ] }, "legn_IncreaseDecreaseThroughReclassificationOfVestedRestrictedStockEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20260630", "localname": "IncreaseDecreaseThroughReclassificationOfVestedRestrictedStockEquity", "crdr": "credit", "presentation": [ "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Reclassification of vested restricted share units", "label": "Increase Decrease Through Reclassification Of Vested Restricted Stock Equity", "documentation": "Increase (decrease) through reclassification of vested restricted stock, equity." } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseThroughSharebasedPaymentTransactions", "crdr": "credit", "presentation": [ "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation expense", "label": "Increase (decrease) through share-based payment transactions, equity" } }, "en": { "role": { "documentation": "The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]" } } }, "auth_ref": [ "r119" ] }, "legn_IncreaseInLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20260630", "localname": "IncreaseInLeaseLiabilities", "crdr": "credit", "presentation": [ "http://legendbiotech.com/role/LEASESSummaryofLeaseLiabilitiesMeasuredatPresentValueofLeasePaymentstobeMadeOverLeaseTermDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additions", "label": "Increase In Lease Liabilities", "documentation": "Increase in lease liabilities." } } }, "auth_ref": [] }, "legn_IncreaseOfLeaseLiabilitiesBalance": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20260630", "localname": "IncreaseOfLeaseLiabilitiesBalance", "crdr": "credit", "presentation": [ "http://legendbiotech.com/role/LEASESSummaryofLeaseLiabilitiesMeasuredatPresentValueofLeasePaymentstobeMadeOverLeaseTermDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accretion of interest recognized during the period", "label": "Increase Of Lease Liabilities Balance", "documentation": "Increase of lease liabilities balance." } } }, "auth_ref": [] }, "legn_InterestBearingBorrowingsFundedInterestsAccrued": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20260630", "localname": "InterestBearingBorrowingsFundedInterestsAccrued", "crdr": "debit", "presentation": [ "http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest accrued on funding advances", "label": "Interest Bearing Borrowings Funded Interests Accrued", "documentation": "Interest bearing borrowings funded interests accrued." } } }, "auth_ref": [] }, "legn_InterestBearingBorrowingsFundingAdvances": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20260630", "localname": "InterestBearingBorrowingsFundingAdvances", "crdr": "credit", "presentation": [ "http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest bearing borrowings, funding advances", "label": "Interest Bearing Borrowings, Funding Advances", "documentation": "Interest Bearing Borrowings, Funding Advances" } } }, "auth_ref": [] }, "legn_InterestBearingBorrowingsFundingAdvancesIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20260630", "localname": "InterestBearingBorrowingsFundingAdvancesIncreaseDecrease", "crdr": "credit", "presentation": [ "http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Advanced funding principal balance increase (decrease)", "label": "Interest Bearing Borrowings, Funding Advances, Increase (Decrease)", "documentation": "Interest Bearing Borrowings, Funding Advances, Increase (Decrease)" } } }, "auth_ref": [] }, "legn_InterestBearingBorrowingsFundingAdvancesNetOfPreTaxProfitReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20260630", "localname": "InterestBearingBorrowingsFundingAdvancesNetOfPreTaxProfitReceivable", "crdr": "credit", "presentation": [ "http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding principal balance", "label": "Interest Bearing Borrowings, Funding Advances, Net of Pre-Tax Profit Receivable", "documentation": "Interest Bearing Borrowings, Funding Advances, Net of Pre-Tax Profit Receivable" } } }, "auth_ref": [] }, "ifrs-full_InterestExpenseOnBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InterestExpenseOnBorrowings", "crdr": "debit", "presentation": [ "http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest expense on borrowings", "label": "Interest expense on borrowings" } } }, "auth_ref": [ "r187" ] }, "ifrs-full_Inventories": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Inventories", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 1.0 }, "http://legendbiotech.com/role/COLLABORATIONINVENTORIESNETSummaryofInventoriesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://legendbiotech.com/role/COLLABORATIONINVENTORIESNETSummaryofInventoriesDetails", "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "Collaboration inventories, net", "totalLabel": "Total collaboration inventories, net", "label": "Current inventories" } }, "en": { "role": { "documentation": "The amount of current inventories. [Refer: Inventories]" } } }, "auth_ref": [ "r6", "r87", "r123", "r169" ] }, "legn_InventoryReserve": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20260630", "localname": "InventoryReserve", "crdr": "credit", "presentation": [ "http://legendbiotech.com/role/COLLABORATIONINVENTORIESNETAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory reserve", "label": "Inventory reserve", "documentation": "Inventory reserve" } } }, "auth_ref": [] }, "ifrs-full_IssuedCapital": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IssuedCapital", "crdr": "credit", "calculation": { "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofSharesDetails", "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "Share capital", "verboseLabel": "Issued and fully paid amount", "label": "Issued capital" } }, "en": { "role": { "documentation": "The nominal value of capital issued." } } }, "auth_ref": [ "r165", "r172" ] }, "ifrs-full_IssuedCapitalMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IssuedCapitalMember", "presentation": [ "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMAdditionalInformationDetails", "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofMovementsintheCompanysShareCapitalandSharePremiumDetails", "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Share capital", "verboseLabel": "Number of shares in issue", "label": "Issued capital [member]" } }, "en": { "role": { "documentation": "This member stands for a component of equity representing issued capital." } } }, "auth_ref": [ "r120" ] }, "legn_JanssenMember": { "xbrltype": "domainItemType", "nsuri": "http://legendbiotech.com/20260630", "localname": "JanssenMember", "presentation": [ "http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGAdditionalInformationDetails", "http://legendbiotech.com/role/LEASESAdditionalInformationDetails", "http://legendbiotech.com/role/REVENUESummaryofAnalysisofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Janssen", "label": "Janssen [Member]", "documentation": "Janssen" } } }, "auth_ref": [] }, "ifrs-full_LandMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LandMember", "presentation": [ "http://legendbiotech.com/role/LEASESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Leasehold land", "label": "Land [member]" } }, "en": { "role": { "documentation": "This member stands for a class of property, plant and equipment representing land held by the entity for use in operations. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r144" ] }, "legn_LeaseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://legendbiotech.com/20260630", "localname": "LeaseAbstract", "lang": { "en-us": { "role": { "label": "Lease [Abstract]", "documentation": "Lease abstract." } } }, "auth_ref": [] }, "legn_LeaseCommitmentPercentageOfFutureLeasePaymentsExpectedUnderProfitSharingAgreement": { "xbrltype": "percentItemType", "nsuri": "http://legendbiotech.com/20260630", "localname": "LeaseCommitmentPercentageOfFutureLeasePaymentsExpectedUnderProfitSharingAgreement", "presentation": [ "http://legendbiotech.com/role/LEASESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease commitment, percentage of future lease payments expected under profit Sharing agreement", "label": "Lease Commitment, Percentage of Future Lease Payments Expected Under Profit Sharing Agreement", "documentation": "Lease Commitment, Percentage of Future Lease Payments Expected Under Profit Sharing Agreement" } } }, "auth_ref": [] }, "ifrs-full_LeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LeaseLiabilities", "crdr": "credit", "calculation": { "http://legendbiotech.com/role/LEASESSummaryofLeaseLiabilitiesMeasuredatPresentValueofLeasePaymentstobeMadeOverLeaseTermDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://legendbiotech.com/role/LEASESAdditionalInformationDetails", "http://legendbiotech.com/role/LEASESSummaryofLeaseLiabilitiesMeasuredatPresentValueofLeasePaymentstobeMadeOverLeaseTermDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease liabilities", "periodStartLabel": "Carrying amount at January 1, 2026", "periodEndLabel": "Carrying amount at June 30, 2026", "totalLabel": "Carrying amount at June 30, 2026", "label": "Lease liabilities" } }, "en": { "role": { "documentation": "The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration." } } }, "auth_ref": [ "r49" ] }, "ifrs-full_LeaseLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LeaseLiabilitiesAbstract", "presentation": [ "http://legendbiotech.com/role/LEASESSummaryofLeaseLiabilitiesMeasuredatPresentValueofLeasePaymentstobeMadeOverLeaseTermDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Analyzed into:", "label": "Lease liabilities [abstract]" } } }, "auth_ref": [] }, "ifrs-full_LeaseLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LeaseLiabilitiesMember", "presentation": [ "http://legendbiotech.com/role/LEASESSummaryofLeaseLiabilitiesMeasuredatPresentValueofLeasePaymentstobeMadeOverLeaseTermDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease liabilities", "label": "Lease liabilities [member]" } }, "en": { "role": { "documentation": "This member stands for lease liabilities. [Refer: Lease liabilities]" } } }, "auth_ref": [ "r151", "r154" ] }, "legn_LeasesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://legendbiotech.com/20260630", "localname": "LeasesLineItems", "presentation": [ "http://legendbiotech.com/role/LEASESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Leases [Line Items]", "label": "Leases [Line Items]", "documentation": "Leases line items." } } }, "auth_ref": [] }, "legn_LeasesRollForward": { "xbrltype": "stringItemType", "nsuri": "http://legendbiotech.com/20260630", "localname": "LeasesRollForward", "presentation": [ "http://legendbiotech.com/role/LEASESSummaryofLeaseLiabilitiesMeasuredatPresentValueofLeasePaymentstobeMadeOverLeaseTermDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Leases [Roll Forward]", "label": "Leases [Roll Forward]", "documentation": "Leases" } } }, "auth_ref": [] }, "legn_LeasesTable": { "xbrltype": "stringItemType", "nsuri": "http://legendbiotech.com/20260630", "localname": "LeasesTable", "presentation": [ "http://legendbiotech.com/role/LEASESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Leases [Table]", "label": "Leases [Table]", "documentation": "Leases table." } } }, "auth_ref": [] }, "legn_LesseeLeaseLiabilitiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://legendbiotech.com/20260630", "localname": "LesseeLeaseLiabilitiesTextBlock", "presentation": [ "http://legendbiotech.com/role/LEASESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Lease Liabilities Measured at Present Value of Lease Payments to be Made Over Lease Term", "label": "Lessee Lease Liabilities [Text Block]", "documentation": "Lessee lease liabilities text block." } } }, "auth_ref": [] }, "legn_LesseeLeasingArrangementsLeasesTerm": { "xbrltype": "durationItemType", "nsuri": "http://legendbiotech.com/20260630", "localname": "LesseeLeasingArrangementsLeasesTerm", "presentation": [ "http://legendbiotech.com/role/LEASESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, lease terms", "label": "Lessee Leasing Arrangements Leases Term", "documentation": "Lessee leasing arrangements leases term." } } }, "auth_ref": [] }, "ifrs-full_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL LIABILITIES", "label": "Liabilities" } }, "en": { "role": { "documentation": "The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits." } } }, "auth_ref": [ "r41", "r42", "r43", "r67", "r71", "r107", "r108", "r126" ] }, "ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LiabilitiesArisingFromFinancingActivitiesAxis", "presentation": [ "http://legendbiotech.com/role/LEASESSummaryofLeaseLiabilitiesMeasuredatPresentValueofLeasePaymentstobeMadeOverLeaseTermDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities arising from financing activities [axis]", "label": "Liabilities arising from financing activities [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r89", "r152" ] }, "ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LiabilitiesArisingFromFinancingActivitiesDomain", "presentation": [ "http://legendbiotech.com/role/LEASESSummaryofLeaseLiabilitiesMeasuredatPresentValueofLeasePaymentstobeMadeOverLeaseTermDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities arising from financing activities [domain]", "label": "Liabilities arising from financing activities [domain]" } }, "en": { "role": { "documentation": "This member stands for liabilities arising from financing activities. It also represents the standard value for the 'Liabilities arising from financing activities' axis if no other member is used. [Refer: Liabilities arising from financing activities]" } } }, "auth_ref": [ "r89", "r152" ] }, "ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "MajorComponentsOfTaxExpenseIncomeAbstract", "lang": { "en-us": { "role": { "label": "Major components of tax expense (income) [abstract]" } } }, "auth_ref": [] }, "legn_NonCashRepaymentOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20260630", "localname": "NonCashRepaymentOfDebt", "crdr": "credit", "presentation": [ "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash repayment of debt", "label": "Non-Cash Repayment Of Debt", "documentation": "Non-Cash Repayment Of Debt" } } }, "auth_ref": [] }, "ifrs-full_NoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentAssets", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "totalLabel": "Total non-current assets", "label": "Non-current assets" } }, "en": { "role": { "documentation": "The amount of assets that do not meet the definition of current assets. [Refer: Current assets]" } } }, "auth_ref": [ "r33", "r127", "r155" ] }, "ifrs-full_NoncurrentAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentAssetsAbstract", "presentation": [ "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "NON-CURRENT ASSETS", "label": "Non-current assets [abstract]" } } }, "auth_ref": [] }, "ifrs-full_NoncurrentFinanceLeaseReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentFinanceLeaseReceivables", "crdr": "debit", "presentation": [ "http://legendbiotech.com/role/LEASESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-current finance lease receivables", "label": "Non-current finance lease receivables" } }, "en": { "role": { "documentation": "The amount of non-current finance lease receivables. [Refer: Finance lease receivables]" } } }, "auth_ref": [ "r188" ] }, "ifrs-full_NoncurrentLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentLeaseLiabilities", "crdr": "credit", "calculation": { "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 1.0 }, "http://legendbiotech.com/role/LEASESSummaryofLeaseLiabilitiesMeasuredatPresentValueofLeasePaymentstobeMadeOverLeaseTermDetails": { "parentTag": "ifrs-full_LeaseLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://legendbiotech.com/role/LEASESSummaryofLeaseLiabilitiesMeasuredatPresentValueofLeasePaymentstobeMadeOverLeaseTermDetails", "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "Lease liabilities long term", "verboseLabel": "Non-current portion", "label": "Non-current lease liabilities" } }, "en": { "role": { "documentation": "The amount of non-current lease liabilities. [Refer: Lease liabilities]" } } }, "auth_ref": [ "r49" ] }, "ifrs-full_NoncurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentLiabilities", "crdr": "credit", "calculation": { "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "totalLabel": "Total non-current liabilities", "label": "Non-current liabilities" } }, "en": { "role": { "documentation": "The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]" } } }, "auth_ref": [ "r35", "r128", "r155" ] }, "ifrs-full_NoncurrentLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentLiabilitiesAbstract", "presentation": [ "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "NON-CURRENT LIABILITIES", "label": "Non-current liabilities [abstract]" } } }, "auth_ref": [] }, "ifrs-full_NoncurrentPortionOfNoncurrentLoansReceived": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentPortionOfNoncurrentLoansReceived", "crdr": "credit", "presentation": [ "http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Collaboration interest-bearing advanced funding", "label": "Non-current portion of non-current loans received" } }, "en": { "role": { "documentation": "The non-current portion of non-current loans received. [Refer: Loans received]" } } }, "auth_ref": [ "r187" ] }, "legn_NovartisMember": { "xbrltype": "domainItemType", "nsuri": "http://legendbiotech.com/20260630", "localname": "NovartisMember", "presentation": [ "http://legendbiotech.com/role/REVENUESummaryofAnalysisofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Novartis", "label": "Novartis [Member]", "documentation": "Novartis" } } }, "auth_ref": [] }, "ifrs-full_NumberOfSharesAuthorised": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfSharesAuthorised", "presentation": [ "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ordinary shares authorized (in shares)", "label": "Number of shares authorised" } }, "en": { "role": { "documentation": "The number of shares authorised." } } }, "auth_ref": [ "r82", "r109", "r131" ] }, "ifrs-full_NumberOfSharesIssuedAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfSharesIssuedAbstract", "presentation": [ "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Issued and fully paid:", "label": "Number of shares issued [abstract]" } } }, "auth_ref": [] }, "ifrs-full_NumberOfSharesIssuedAndFullyPaid": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfSharesIssuedAndFullyPaid", "presentation": [ "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ordinary shares issued and fully paid (in shares)", "label": "Number of shares issued and fully paid" } }, "en": { "role": { "documentation": "The number of shares issued by the entity, for which full payment has been received." } } }, "auth_ref": [ "r83", "r110", "r132" ] }, "legn_OngoingLeasePaymentsUnderTheLandLease": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20260630", "localname": "OngoingLeasePaymentsUnderTheLandLease", "crdr": "debit", "presentation": [ "http://legendbiotech.com/role/LEASESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ongoing lease payments", "label": "Ongoing Lease Payments Under The Land Lease", "documentation": "Ongoing lease payments under the land lease." } } }, "auth_ref": [] }, "ifrs-full_OrdinarySharesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OrdinarySharesMember", "presentation": [ "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ordinary Shares", "label": "Ordinary shares [member]" } }, "en": { "role": { "documentation": "This member stands for equity instruments that are subordinate to all other classes of equity instruments." } } }, "auth_ref": [ "r191" ] }, "ifrs-full_OtherAdjustmentsToReconcileProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherAdjustmentsToReconcileProfitLoss", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Other, net", "label": "Other adjustments to reconcile profit (loss)" } } }, "auth_ref": [ "r19" ] }, "legn_OtherCollaborationReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20260630", "localname": "OtherCollaborationReceivables", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSDetails": { "parentTag": "legn_PrepaymentsOtherReceivablesAndOtherAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other collaboration receivables", "label": "Other Collaboration Receivables", "documentation": "Other Collaboration Receivables" } } }, "auth_ref": [] }, "ifrs-full_OtherComprehensiveIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherComprehensiveIncome", "crdr": "credit", "calculation": { "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOMELOSS": { "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOMELOSS" ], "lang": { "en-us": { "role": { "totalLabel": "Other comprehensive income (loss), net of tax", "label": "Other comprehensive income" } } }, "auth_ref": [ "r38", "r118", "r137", "r142" ] }, "ifrs-full_OtherComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherComprehensiveIncomeAbstract", "presentation": [ "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive (loss) income", "label": "Other comprehensive income [abstract]" } } }, "auth_ref": [] }, "ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation", "crdr": "credit", "calculation": { "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOMELOSS": { "parentTag": "ifrs-full_OtherComprehensiveIncome", "weight": 1.0, "order": 1.0 }, "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY": { "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY", "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOMELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "Exchange differences on translation of foreign operations", "verboseLabel": "Exchange differences on translation of foreign operations", "label": "Other comprehensive income, net of tax, exchange differences on translation of foreign operations" } }, "en": { "role": { "documentation": "The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r129", "r142" ] }, "ifrs-full_OtherCurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherCurrentAssets", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSDetails": { "parentTag": "legn_PrepaymentsOtherReceivablesAndOtherAssets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other current assets", "label": "Other current assets" } }, "en": { "role": { "documentation": "The amount of current assets that the entity does not separately disclose in the same statement or note. [Refer: Current assets]" } } }, "auth_ref": [ "r188" ] }, "ifrs-full_OtherCurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherCurrentLiabilities", "crdr": "credit", "calculation": { "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "Other current liabilities", "label": "Other current liabilities" } }, "en": { "role": { "documentation": "The amount of current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Current liabilities]" } } }, "auth_ref": [ "r188" ] }, "ifrs-full_OtherExpenseByFunction": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherExpenseByFunction", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOMELOSS": { "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOMELOSS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other operating expenses", "label": "Other expense, by function" } } }, "auth_ref": [ "r11", "r143", "r167" ] }, "ifrs-full_OtherGainsLosses": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherGainsLosses", "crdr": "credit", "calculation": { "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOMELOSS": { "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": 1.0, "order": 4.0 }, "http://legendbiotech.com/role/OTHEREXPENSENETDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://legendbiotech.com/role/OTHEREXPENSENETDetails", "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOMELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "Other expense, net", "totalLabel": "Total other expense, net", "label": "Other gains (losses)" } } }, "auth_ref": [ "r184", "r185" ] }, "legn_OtherMiscellaneousIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20260630", "localname": "OtherMiscellaneousIncomeExpense", "crdr": "credit", "calculation": { "http://legendbiotech.com/role/OTHEREXPENSENETDetails": { "parentTag": "ifrs-full_OtherGainsLosses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://legendbiotech.com/role/OTHEREXPENSENETDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other income, net", "label": "Other Miscellaneous Income (Expense)", "documentation": "Other Miscellaneous Income (Expense)" } } }, "auth_ref": [] }, "ifrs-full_OtherNoncurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherNoncurrentLiabilities", "crdr": "credit", "calculation": { "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "Other non-current liabilities", "label": "Other non-current liabilities" } }, "en": { "role": { "documentation": "The amount of non-current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Non-current liabilities]" } } }, "auth_ref": [ "r188" ] }, "ifrs-full_OtherNoncurrentNonfinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherNoncurrentNonfinancialAssets", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "Other non-current assets", "label": "Other non-current non-financial assets" } }, "en": { "role": { "documentation": "The amount of non-current non-financial assets that the entity does not separately disclose in the same statement or note. [Refer: Financial assets]" } } }, "auth_ref": [ "r188" ] }, "legn_OtherPayablesAndAccrualsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20260630", "localname": "OtherPayablesAndAccrualsCurrent", "crdr": "credit", "calculation": { "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 2.0 }, "http://legendbiotech.com/role/OTHERPAYABLESANDACCRUALSDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://legendbiotech.com/role/OTHERPAYABLESANDACCRUALSDetails", "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "Other payables and accruals", "totalLabel": "Total", "label": "Other Payables And Accruals Current", "documentation": "Other payables and accruals, current." } } }, "auth_ref": [] }, "ifrs-full_OtherReserves": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherReserves", "crdr": "credit", "calculation": { "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY", "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "Reserves", "label": "Other reserves" } }, "en": { "role": { "documentation": "A component of equity representing reserves within equity, not including retained earnings. [Refer: Retained earnings]" } } }, "auth_ref": [ "r165", "r172" ] }, "ifrs-full_OtherRevenue": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherRevenue", "crdr": "credit", "calculation": { "http://legendbiotech.com/role/REVENUESummaryofAnalysisofRevenueDetails": { "parentTag": "legn_RevenueFromLicensingOfIntellectualPropertyAndOther", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://legendbiotech.com/role/REVENUESummaryofAnalysisofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other revenue", "label": "Other revenue" } } }, "auth_ref": [ "r187" ] }, "legn_OutsideTheUnitedStatesOfAmericaMember": { "xbrltype": "domainItemType", "nsuri": "http://legendbiotech.com/20260630", "localname": "OutsideTheUnitedStatesOfAmericaMember", "presentation": [ "http://legendbiotech.com/role/REVENUESummaryofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Outside the United States of America", "label": "Outside the United States of America [Member]", "documentation": "Outside the United States of America" } } }, "auth_ref": [] }, "ifrs-full_ParValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ParValuePerShare", "presentation": [ "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofSharesDetails" ], "lang": { "en-us": { "role": { "netLabel": "Authorized, price per share (in dollars per share)", "terseLabel": "Price per share (in dollars per share)", "label": "Par value per share" } }, "en": { "role": { "documentation": "The nominal value per share." } } }, "auth_ref": [ "r84", "r111", "r133" ] }, "ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities", "crdr": "credit", "calculation": { "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Principal portion of lease payments", "label": "Payments of lease liabilities, classified as financing activities" } }, "en": { "role": { "documentation": "The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]" } } }, "auth_ref": [ "r150" ] }, "legn_PrepaymentToCollaboratorForCollaborationRightOfUseAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20260630", "localname": "PrepaymentToCollaboratorForCollaborationRightOfUseAssets", "crdr": "credit", "calculation": { "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Prepayment to collaborator for collaboration assets", "label": "Prepayment To Collaborator For Collaboration Right Of Use Assets", "documentation": "Prepayment To Collaborator For Collaboration Right Of Use Assets" } } }, "auth_ref": [] }, "ifrs-full_Prepayments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Prepayments", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSDetails": { "parentTag": "legn_PrepaymentsOtherReceivablesAndOtherAssets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Prepayments", "label": "Prepayments" } }, "en": { "role": { "documentation": "Receivables that represent amounts paid for goods and services before they have been delivered." } } }, "auth_ref": [ "r163", "r170" ] }, "legn_PrepaymentsOtherReceivablesAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20260630", "localname": "PrepaymentsOtherReceivablesAndOtherAssets", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Prepayments Other Receivables And Other Assets", "documentation": "Prepayments, other receivables and other assets." } } }, "auth_ref": [] }, "legn_PrepaymentsOtherReceivablesAndOtherAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://legendbiotech.com/20260630", "localname": "PrepaymentsOtherReceivablesAndOtherAssetsMember", "presentation": [ "http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepayments Other Receivable and Other Assets", "label": "Prepayments Other Receivables And Other Assets [Member]", "documentation": "Prepayments other receivables and other assets.," } } }, "auth_ref": [] }, "ifrs-full_ProceedsFromExerciseOfOptions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProceedsFromExerciseOfOptions", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from exercise of share options", "label": "Proceeds from exercise of options" } }, "en": { "role": { "documentation": "The cash inflow from the exercise of options." } } }, "auth_ref": [ "r175" ] }, "ifrs-full_ProceedsFromIssuingShares": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProceedsFromIssuingShares", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMAdditionalInformationDetails", "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from issuance of ordinary shares, net", "label": "Proceeds from issuing shares" } }, "en": { "role": { "documentation": "The cash inflow from issuing shares." } } }, "auth_ref": [ "r148" ] }, "legn_ProceedsFromTheMaturityOfTimeDeposits": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20260630", "localname": "ProceedsFromTheMaturityOfTimeDeposits", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from the maturity of time deposits", "label": "Proceeds From The Maturity of Time Deposits", "documentation": "Decrease in time deposits." } } }, "auth_ref": [] }, "ifrs-full_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOMELOSS": { "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0, "order": 1.0 }, "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY": { "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://legendbiotech.com/role/EARNINGSLOSSPERSHARESummaryofCalculationsofBasicandDilutedEarningsLossperShareDetails", "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY", "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOMELOSS" ], "lang": { "en-us": { "role": { "totalLabel": "Net income (loss)", "terseLabel": "Loss for the period", "verboseLabel": "Net income (loss)", "label": "Profit (loss)" } }, "en": { "role": { "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r29", "r31", "r67", "r69", "r101", "r104", "r117", "r136", "r155", "r159" ] }, "ifrs-full_ProfitLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProfitLossBeforeTax", "crdr": "credit", "calculation": { "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOMELOSS": { "parentTag": "ifrs-full_ProfitLoss", "weight": 1.0, "order": 1.0 }, "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOMELOSS" ], "lang": { "en-us": { "role": { "totalLabel": "Income (loss) before tax", "terseLabel": "Income (loss) before tax", "label": "Profit (loss) before tax" } } }, "auth_ref": [ "r59", "r160", "r161", "r166", "r167" ] }, "ifrs-full_ProfitLossFromOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProfitLossFromOperatingActivities", "crdr": "credit", "calculation": { "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOMELOSS": { "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOMELOSS" ], "lang": { "en-us": { "role": { "totalLabel": "Operating income (loss)", "label": "Profit (loss) from operating activities" } } }, "auth_ref": [ "r145", "r192" ] }, "ifrs-full_PropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PropertyPlantAndEquipment", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment", "label": "Property, plant and equipment" } }, "en": { "role": { "documentation": "The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period. Note that right-of-use assets are not included. [Contrast: Property, plant and equipment including right-of-use assets]" } } }, "auth_ref": [ "r4", "r96", "r122" ] }, "ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities", "crdr": "credit", "calculation": { "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Purchase of property, plant and equipment", "label": "Purchase of property, plant and equipment, classified as investing activities" } }, "en": { "role": { "documentation": "The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r147" ] }, "legn_PurchaseOfTimeDeposits": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20260630", "localname": "PurchaseOfTimeDeposits", "crdr": "credit", "calculation": { "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Purchase of time deposits", "label": "Purchase of Time Deposits", "documentation": "Addition in time deposits." } } }, "auth_ref": [] }, "ifrs-full_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RangeAxis", "presentation": [ "http://legendbiotech.com/role/LEASESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Range [axis]", "label": "Range [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r24", "r44", "r57", "r58", "r90", "r156", "r157", "r182" ] }, "ifrs-full_RangeDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RangeDomain", "presentation": [ "http://legendbiotech.com/role/LEASESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Range [domain]", "label": "Range [domain]" } }, "en": { "role": { "documentation": "This member stands for aggregate ranges. It also represents the standard value for the 'Range' axis if no other member is used." } } }, "auth_ref": [ "r24", "r44", "r57", "r58", "r90", "r156", "r157", "r182" ] }, "ifrs-full_RawMaterials": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RawMaterials", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/COLLABORATIONINVENTORIESNETSummaryofInventoriesDetails": { "parentTag": "ifrs-full_Inventories", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://legendbiotech.com/role/COLLABORATIONINVENTORIESNETSummaryofInventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Raw materials", "label": "Current raw materials" } }, "en": { "role": { "documentation": "A classification of current inventory representing the amount of assets to be consumed in the production process or in the rendering of services. [Refer: Inventories]" } } }, "auth_ref": [ "r164", "r171", "r174" ] }, "legn_ReclassificationOfVestedRestrictedStockUnitsNumberOfSharesInIssue": { "xbrltype": "sharesItemType", "nsuri": "http://legendbiotech.com/20260630", "localname": "ReclassificationOfVestedRestrictedStockUnitsNumberOfSharesInIssue", "presentation": [ "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofMovementsintheCompanysShareCapitalandSharePremiumDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reclassification of vesting of restricted share units (in shares)", "label": "Reclassification Of Vested Restricted Stock Units Number Of Shares In Issue", "documentation": "Reclassification of vested restricted stock units, number of shares in issue." } } }, "auth_ref": [] }, "legn_ReclassificationOfVestedRestrictedStockUnitsShareCapitalAndSharePremium": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20260630", "localname": "ReclassificationOfVestedRestrictedStockUnitsShareCapitalAndSharePremium", "crdr": "credit", "presentation": [ "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofMovementsintheCompanysShareCapitalandSharePremiumDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reclassification of vesting of restricted share units", "label": "Reclassification Of Vested Restricted Stock Units Share Capital And Share Premium", "documentation": "Reclassification of vested restricted stock units, share capital and share premium." } } }, "auth_ref": [] }, "legn_RelatedPartySublicenseMember": { "xbrltype": "domainItemType", "nsuri": "http://legendbiotech.com/20260630", "localname": "RelatedPartySublicenseMember", "presentation": [ "http://legendbiotech.com/role/REVENUESummaryofAnalysisofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Sublicense", "label": "Related Party Sublicense [Member]", "documentation": "Related Party Sublicense" } } }, "auth_ref": [] }, "ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RepaymentsOfBorrowingsClassifiedAsFinancingActivities", "crdr": "credit", "calculation": { "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Repayment of debt", "label": "Repayments of borrowings, classified as financing activities" } }, "en": { "role": { "documentation": "The cash outflow to settle borrowings, classified as financing activities. [Refer: Borrowings]" } } }, "auth_ref": [ "r149" ] }, "ifrs-full_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOMELOSS": { "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOMELOSS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Research and development expenses", "label": "Research and development expense" } } }, "auth_ref": [ "r17", "r102" ] }, "ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ReserveOfExchangeDifferencesOnTranslationMember", "presentation": [ "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency translation reserve", "label": "Reserve of exchange differences on translation [member]" } }, "en": { "role": { "documentation": "This member stands for a component of equity representing accumulated exchange differences on the translation of financial statements recognised in other comprehensive income. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r9", "r99", "r168" ] }, "ifrs-full_ReserveOfSharebasedPaymentsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ReserveOfSharebasedPaymentsMember", "presentation": [ "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation reserves", "label": "Reserve of share-based payments [member]" } }, "en": { "role": { "documentation": "This member stands for a component of equity resulting from share-based payments." } } }, "auth_ref": [ "r168" ] }, "ifrs-full_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RetainedEarningsMember", "presentation": [ "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Retained accumulated losses", "label": "Retained earnings [member]" } }, "en": { "role": { "documentation": "This member stands for a component of equity representing an entity's cumulative undistributed earnings or deficit." } } }, "auth_ref": [ "r120", "r168" ] }, "ifrs-full_Revenue": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Revenue", "crdr": "credit", "calculation": { "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOMELOSS": { "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOMELOSS" ], "lang": { "en-us": { "role": { "totalLabel": "Total revenue", "label": "Revenue" } } }, "auth_ref": [ "r37", "r59", "r65", "r68", "r72", "r73", "r75", "r139", "r155", "r166", "r167" ] }, "ifrs-full_RevenueAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RevenueAbstract", "presentation": [ "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOMELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "REVENUE", "label": "Revenue [abstract]" } } }, "auth_ref": [] }, "ifrs-full_RevenueFromContractsWithCustomers": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RevenueFromContractsWithCustomers", "crdr": "credit", "calculation": { "http://legendbiotech.com/role/REVENUESummaryofAnalysisofRevenueDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://legendbiotech.com/role/REVENUEAnalysisofTimingofTransferofGoodsorServicesDetails", "http://legendbiotech.com/role/REVENUESummaryofAnalysisofRevenueDetails", "http://legendbiotech.com/role/REVENUESummaryofRevenueDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total revenue", "terseLabel": "Total revenue", "label": "Revenue from contracts with customers" } } }, "auth_ref": [ "r46", "r47", "r76" ] }, "legn_RevenueFromLicensingOfIntellectualProperty": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20260630", "localname": "RevenueFromLicensingOfIntellectualProperty", "crdr": "credit", "calculation": { "http://legendbiotech.com/role/REVENUESummaryofAnalysisofRevenueDetails": { "parentTag": "legn_RevenueFromLicensingOfIntellectualPropertyAndOther", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://legendbiotech.com/role/REVENUESummaryofAnalysisofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "License revenue", "label": "Revenue From Licensing Of Intellectual Property", "documentation": "Revenue from licensing of intellectual property." } } }, "auth_ref": [] }, "legn_RevenueFromLicensingOfIntellectualPropertyAndOther": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20260630", "localname": "RevenueFromLicensingOfIntellectualPropertyAndOther", "crdr": "credit", "calculation": { "http://legendbiotech.com/role/REVENUESummaryofAnalysisofRevenueDetails": { "parentTag": "ifrs-full_RevenueFromContractsWithCustomers", "weight": 1.0, "order": 1.0 }, "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOMELOSS": { "parentTag": "ifrs-full_Revenue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://legendbiotech.com/role/REVENUESummaryofAnalysisofRevenueDetails", "http://legendbiotech.com/role/REVENUESummaryofRevenueDetails", "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOMELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "License and other revenue - total", "totalLabel": "License and other revenue - total", "label": "Revenue From Licensing Of Intellectual Property and Other", "documentation": "Revenue from licensing of intellectual property." } } }, "auth_ref": [] }, "legn_RightOfUseAssetsRollForward": { "xbrltype": "stringItemType", "nsuri": "http://legendbiotech.com/20260630", "localname": "RightOfUseAssetsRollForward", "presentation": [ "http://legendbiotech.com/role/LEASESSummaryofCarryingAmountsofTheRightofuseAssetsandMovementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Right-of-Use Assets [Roll Forward]", "label": "Right-of-Use Assets [Roll Forward]", "documentation": "Right-of-Use Assets" } } }, "auth_ref": [] }, "ifrs-full_RightofuseAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RightofuseAssets", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://legendbiotech.com/role/LEASESSummaryofCarryingAmountsofTheRightofuseAssetsandMovementsDetails", "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "Right-of-use assets", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Right-of-use assets" } }, "en": { "role": { "documentation": "The amount of assets that represent a lessee's right to use an underlying asset for the lease term that do not meet the definition of investment property. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee." } } }, "auth_ref": [ "r48", "r53", "r80" ] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "SegmentGeographicalDomain", "presentation": [ "http://legendbiotech.com/role/REVENUESummaryofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Domain]", "label": "Geographical [Domain]" } } }, "auth_ref": [] }, "legn_SellingAndDistributionExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20260630", "localname": "SellingAndDistributionExpenses", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOMELOSS": { "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOMELOSS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Selling and distribution expenses", "label": "Selling And Distribution Expenses", "documentation": "Selling and distribution expenses." } } }, "auth_ref": [] }, "legn_ShareCapitalAndSharePremium": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20260630", "localname": "ShareCapitalAndSharePremium", "crdr": "credit", "presentation": [ "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofMovementsintheCompanysShareCapitalandSharePremiumDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Share Capital And Share Premium", "documentation": "Share capital and share premium." } } }, "auth_ref": [] }, "legn_ShareCapitalAndSharePremiumNumberOfSharesInIssue": { "xbrltype": "sharesItemType", "nsuri": "http://legendbiotech.com/20260630", "localname": "ShareCapitalAndSharePremiumNumberOfSharesInIssue", "presentation": [ "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofMovementsintheCompanysShareCapitalandSharePremiumDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance (in shares)", "periodEndLabel": "Ending balance (in shares)", "label": "Share Capital And Share Premium Number Of Shares In Issue", "documentation": "Share capital and share premium, number of shares in issue." } } }, "auth_ref": [] }, "legn_ShareCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://legendbiotech.com/20260630", "localname": "ShareCapitalMember", "presentation": [ "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofMovementsintheCompanysShareCapitalandSharePremiumDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share capital", "label": "Share Capital [Member]", "documentation": "Share capital." } } }, "auth_ref": [] }, "legn_ShareCapitalRollForward": { "xbrltype": "stringItemType", "nsuri": "http://legendbiotech.com/20260630", "localname": "ShareCapitalRollForward", "presentation": [ "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofMovementsintheCompanysShareCapitalandSharePremiumDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share Capital [Roll Forward]", "label": "Share Capital [Roll Forward]", "documentation": "Share Capital" } } }, "auth_ref": [] }, "ifrs-full_ShareIssueRelatedCost": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ShareIssueRelatedCost", "crdr": "debit", "presentation": [ "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMAdditionalInformationDetails", "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofMovementsintheCompanysShareCapitalandSharePremiumDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of ordinary shares, net", "label": "Share issue related cost" } } }, "auth_ref": [ "r186" ] }, "ifrs-full_SharePremiumMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SharePremiumMember", "presentation": [ "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofMovementsintheCompanysShareCapitalandSharePremiumDetails", "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Share premium", "label": "Share premium [member]" } }, "en": { "role": { "documentation": "This member stands for the amount received or receivable from issuance of the entity's shares in excess of nominal value." } } }, "auth_ref": [ "r120" ] }, "legn_SharesIssuedOverAllotmentOptionTerm": { "xbrltype": "durationItemType", "nsuri": "http://legendbiotech.com/20260630", "localname": "SharesIssuedOverAllotmentOptionTerm", "presentation": [ "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares issued, over-allotment option, term", "label": "Shares Issued, Over-Allotment Option, Term", "documentation": "Shares Issued, Over-Allotment Option, Term" } } }, "auth_ref": [] }, "legn_SharesIssuedPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://legendbiotech.com/20260630", "localname": "SharesIssuedPricePerShare", "presentation": [ "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares issued price per share (in dollars per share)", "label": "Shares Issued, Price Per Share", "documentation": "Shares Issued, Price Per Share" } } }, "auth_ref": [] }, "ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ShorttermDepositsClassifiedAsCashEquivalents", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_Cash", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Less: Pledged deposits", "label": "Short-term deposits, classified as cash equivalents" } }, "en": { "role": { "documentation": "A classification of cash equivalents representing short-term deposits. [Refer: Cash equivalents]" } } }, "auth_ref": [ "r181" ] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "StatementGeographicalAxis", "presentation": [ "http://legendbiotech.com/role/REVENUESummaryofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Axis]", "label": "Geographical [Axis]" } } }, "auth_ref": [] }, "ifrs-full_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of cash flows [abstract]" } } }, "auth_ref": [] }, "ifrs-full_StatementOfChangesInEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "StatementOfChangesInEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of changes in equity [abstract]" } } }, "auth_ref": [] }, "ifrs-full_StatementOfChangesInEquityLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "StatementOfChangesInEquityLineItems", "presentation": [ "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Statement of changes in equity [line items]", "label": "Statement of changes in equity [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "legn_StatementOfChangesInEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://legendbiotech.com/20260630", "localname": "StatementOfChangesInEquityRollForward", "presentation": [ "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Statement of changes in equity [Roll Forward]", "label": "Statement of changes in equity [Roll Forward]", "documentation": "Statement of changes in equity" } } }, "auth_ref": [] }, "ifrs-full_StatementOfChangesInEquityTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "StatementOfChangesInEquityTable", "presentation": [ "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Statement of changes in equity [table]", "label": "Statement of changes in equity [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to changes in equity." } } }, "auth_ref": [ "r120" ] }, "ifrs-full_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of financial position [abstract]" } } }, "auth_ref": [] }, "legn_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://legendbiotech.com/20260630", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock issued during period shares new issues (in shares)", "label": "Stock Issued During Period Shares New Issues", "documentation": "Stock Issued During Period Shares New Issues" } } }, "auth_ref": [] }, "legn_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20260630", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [ "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of ordinary shares, net", "label": "Stock Issued During Period, Value, New Issues", "documentation": "Stock Issued During Period, Value, New Issues" } } }, "auth_ref": [] }, "legn_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://legendbiotech.com/20260630", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "SUPPLEMENTAL CASH FLOW INFORMATION", "label": "Supplemental Cash Flow Information [Abstract]", "documentation": "Supplemental Cash Flow Information" } } }, "auth_ref": [] }, "legn_TimesDeposits": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20260630", "localname": "TimesDeposits", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "Time deposits", "label": "Times Deposits", "documentation": "Times deposits." } } }, "auth_ref": [] }, "legn_TimesDepositsCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20260630", "localname": "TimesDepositsCurrentAndNoncurrent", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_Cash", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Time deposits", "label": "Times Deposits Current And Noncurrent", "documentation": "Times deposits current and noncurrent." } } }, "auth_ref": [] }, "ifrs-full_TimingOfTransferOfGoodsOrServicesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TimingOfTransferOfGoodsOrServicesAxis", "presentation": [ "http://legendbiotech.com/role/REVENUEAnalysisofTimingofTransferofGoodsorServicesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Timing of transfer of goods or services [axis]", "label": "Timing of transfer of goods or services [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r158", "r162" ] }, "ifrs-full_TimingOfTransferOfGoodsOrServicesDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TimingOfTransferOfGoodsOrServicesDomain", "presentation": [ "http://legendbiotech.com/role/REVENUEAnalysisofTimingofTransferofGoodsorServicesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Timing of transfer of goods or services [domain]", "label": "Timing of transfer of goods or services [domain]" } }, "en": { "role": { "documentation": "This member stands for all timings of the transfer of goods or services in contracts with customers. It also represents the standard value for the 'Timing of transfer of goods or services' axis if no other member is used." } } }, "auth_ref": [ "r158", "r162" ] }, "ifrs-full_TopOfRangeMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TopOfRangeMember", "presentation": [ "http://legendbiotech.com/role/LEASESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Top of Range", "label": "Top of range [member]" } }, "en": { "role": { "documentation": "This member stands for top of a range." } } }, "auth_ref": [ "r24", "r44", "r57", "r58", "r90", "r156", "r157", "r182" ] }, "ifrs-full_TradeAndOtherPayablesToTradeSuppliers": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TradeAndOtherPayablesToTradeSuppliers", "crdr": "credit", "calculation": { "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "Trade payables", "label": "Trade payables" } }, "en": { "role": { "documentation": "The amount of payment due to suppliers for goods and services used in the entity's business." } } }, "auth_ref": [ "r190" ] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2025", "localname": "US", "presentation": [ "http://legendbiotech.com/role/REVENUESummaryofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "United States of America", "label": "UNITED STATES" } } }, "auth_ref": [] }, "ifrs-full_ValueAddedTaxReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ValueAddedTaxReceivables", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSDetails": { "parentTag": "legn_PrepaymentsOtherReceivablesAndOtherAssets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "VAT recoverable", "label": "Value added tax receivables" } }, "en": { "role": { "documentation": "The amount of receivables related to a value added tax." } } }, "auth_ref": [ "r189" ] }, "ifrs-full_WeightedAverageShares": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WeightedAverageShares", "presentation": [ "http://legendbiotech.com/role/EARNINGSLOSSPERSHARESummaryofCalculationsofBasicandDilutedEarningsLossperShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Basic (in shares)", "label": "Weighted average number of ordinary shares used in calculating basic earnings per share" } }, "en": { "role": { "documentation": "The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor." } } }, "auth_ref": [ "r15" ] }, "ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract", "presentation": [ "http://legendbiotech.com/role/EARNINGSLOSSPERSHARESummaryofCalculationsofBasicandDilutedEarningsLossperShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average shares outstanding:", "label": "Weighted average ordinary shares used in calculating basic and diluted earnings per share [abstract]" } } }, "auth_ref": [] }, "ifrs-full_WorkInProgress": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WorkInProgress", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/COLLABORATIONINVENTORIESNETSummaryofInventoriesDetails": { "parentTag": "ifrs-full_Inventories", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://legendbiotech.com/role/COLLABORATIONINVENTORIESNETSummaryofInventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Work-in-process", "label": "Current work in progress" } }, "en": { "role": { "documentation": "A classification of current inventory representing the amount of assets currently in production, which require further processes to be converted into finished goods or services. [Refer: Current finished goods; Inventories]" } } }, "auth_ref": [ "r164", "r171", "r174" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "79", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_79&doctype=Standard", "URIDate": "2025-03-27" }, "r1": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "81", "Subparagraph": "c", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_81_c_i&doctype=Standard", "URIDate": "2025-03-27" }, "r2": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "81", "Subparagraph": "c", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_81_c_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r3": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS12_g79-88_TI", "URIDate": "2025-03-27" }, "r4": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "73", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73_e&doctype=Standard", "URIDate": "2025-03-27" }, "r5": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "73", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73&doctype=Standard", "URIDate": "2025-03-27" }, "r6": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "36", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2025-en-r&anchor=para_36_b&doctype=Standard", "URIDate": "2025-03-27" }, "r7": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "2", "IssueDate": "2025-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS02_g36-39_TI", "URIDate": "2025-03-27" }, "r8": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "21", "IssueDate": "2025-01-01", "Paragraph": "52", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2025-en-r&anchor=para_52_a&doctype=Standard", "URIDate": "2025-03-27" }, "r9": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "21", "IssueDate": "2025-01-01", "Paragraph": "52", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2025-en-r&anchor=para_52_b&doctype=Standard", "URIDate": "2025-03-27" }, "r10": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "26", "IssueDate": "2025-01-01", "Paragraph": "35", "Subparagraph": "b", "Clause": "vi", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2025-en-r&anchor=para_35_b_vi&doctype=Standard", "URIDate": "2025-03-27" }, "r11": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "26", "IssueDate": "2025-01-01", "Paragraph": "35", "Subparagraph": "b", "Clause": "vii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2025-en-r&anchor=para_35_b_vii&doctype=Standard", "URIDate": "2025-03-27" }, "r12": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "26", "IssueDate": "2025-01-01", "Paragraph": "35", "Subparagraph": "b", "Clause": "viii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2025-en-r&anchor=para_35_b_viii&doctype=Standard", "URIDate": "2025-03-27" }, "r13": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2025-01-01", "Paragraph": "66", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_66&doctype=Standard", "URIDate": "2025-03-27" }, "r14": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2025-01-01", "Paragraph": "67", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_67&doctype=Standard", "URIDate": "2025-03-27" }, "r15": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2025-01-01", "Paragraph": "70", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_70_b&doctype=Standard", "URIDate": "2025-03-27" }, "r16": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2025-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS33_g70-73A_TI", "URIDate": "2025-03-27" }, "r17": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "126", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_126&doctype=Standard", "URIDate": "2025-03-27" }, "r18": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "10", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_10&doctype=Standard", "URIDate": "2025-03-27" }, "r19": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "20", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_20&doctype=Standard", "URIDate": "2025-03-27" }, "r20": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "25", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_25&doctype=Standard", "URIDate": "2025-03-27" }, "r21": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "28", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_28&doctype=Standard", "URIDate": "2025-03-27" }, "r22": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35&doctype=Standard", "URIDate": "2025-03-27" }, "r23": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "44B", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_44B_c&doctype=Standard", "URIDate": "2025-03-27" }, "r24": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "44H", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_44H_b_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r25": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_45&doctype=Standard", "URIDate": "2025-03-27" }, "r26": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "50", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_50_d&doctype=Standard", "URIDate": "2025-03-27" }, "r27": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "30", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2025-en-r&anchor=para_30_b&doctype=Standard", "URIDate": "2025-03-27" }, "r28": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "24", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_24_a&doctype=Standard", "URIDate": "2025-03-27" }, "r29": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "24", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_24_b&doctype=Standard", "URIDate": "2025-03-27" }, "r30": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "32", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_32_a_i&doctype=Standard", "URIDate": "2025-03-27" }, "r31": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "32", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_32_a_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r32": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r33": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_ii&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r34": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_iii&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r35": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_iv&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r36": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "ix", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_ix&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r37": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "v", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_v&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r38": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "viii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_viii&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r39": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B13", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r40": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B13", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B13_g&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r41": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "93", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_a&doctype=Standard", "URIDate": "2025-03-27" }, "r42": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "93", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_b&doctype=Standard", "URIDate": "2025-03-27" }, "r43": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "93", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_e&doctype=Standard", "URIDate": "2025-03-27" }, "r44": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "14", "IssueDate": "2025-01-01", "Paragraph": "33", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2025-en-r&anchor=para_33_b&doctype=Standard", "URIDate": "2025-03-27" }, "r45": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2025-01-01", "Paragraph": "105", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_105&doctype=Standard", "URIDate": "2025-03-27" }, "r46": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2025-01-01", "Paragraph": "113", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_113_a&doctype=Standard", "URIDate": "2025-03-27" }, "r47": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2025-01-01", "Paragraph": "114", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_114&doctype=Standard", "URIDate": "2025-03-27" }, "r48": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "47", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_47_a&doctype=Standard", "URIDate": "2025-03-27" }, "r49": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "47", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_47_b&doctype=Standard", "URIDate": "2025-03-27" }, "r50": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "53", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_53_a&doctype=Standard", "URIDate": "2025-03-27" }, "r51": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "53", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_53_g&doctype=Standard", "URIDate": "2025-03-27" }, "r52": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "53", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_53_h&doctype=Standard", "URIDate": "2025-03-27" }, "r53": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "53", "Subparagraph": "j", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_53_j&doctype=Standard", "URIDate": "2025-03-27" }, "r54": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "53", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_53&doctype=Standard", "URIDate": "2025-03-27" }, "r55": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IFRS16_g51-60_TI", "URIDate": "2025-03-27" }, "r56": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Section": "Presentation", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IFRS16_g47-50_TI", "URIDate": "2025-03-27" }, "r57": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "120", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_120&doctype=Standard", "URIDate": "2025-03-27" }, "r58": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_d&doctype=Standard", "URIDate": "2025-03-27" }, "r59": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "5", "IssueDate": "2025-01-01", "Paragraph": "33", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2025-en-r&anchor=para_33_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r60": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35H", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35H&doctype=Standard", "URIDate": "2025-03-27" }, "r61": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35K", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35K&doctype=Standard", "URIDate": "2025-03-27" }, "r62": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35M", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35M&doctype=Standard", "URIDate": "2025-03-27" }, "r63": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "36", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_36&doctype=Standard", "URIDate": "2025-03-27" }, "r64": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "B52", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B52&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r65": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "23", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23_a&doctype=Standard", "URIDate": "2025-03-27" }, "r66": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "23", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23_h&doctype=Standard", "URIDate": "2025-03-27" }, "r67": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "23", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23&doctype=Standard", "URIDate": "2025-03-27" }, "r68": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_a&doctype=Standard", "URIDate": "2025-03-27" }, "r69": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_b&doctype=Standard", "URIDate": "2025-03-27" }, "r70": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_c&doctype=Standard", "URIDate": "2025-03-27" }, "r71": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_d&doctype=Standard", "URIDate": "2025-03-27" }, "r72": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "32", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_32&doctype=Standard", "URIDate": "2025-03-27" }, "r73": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "33", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_33_a&doctype=Standard", "URIDate": "2025-03-27" }, "r74": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_33&doctype=Standard", "URIDate": "2025-03-27" }, "r75": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "34", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_34&doctype=Standard", "URIDate": "2025-03-27" }, "r76": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "103", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_103&doctype=Standard", "URIDate": "2025-03-27" }, "r77": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "115", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_115_a&doctype=Standard", "URIDate": "2025-03-27" }, "r78": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "115", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_115_f&doctype=Standard", "URIDate": "2025-03-27" }, "r79": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "115", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_115_g&doctype=Standard", "URIDate": "2025-03-27" }, "r80": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "115", "Subparagraph": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_115_i&doctype=Standard", "URIDate": "2025-03-27" }, "r81": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "115", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_115&doctype=Standard", "URIDate": "2025-03-27" }, "r82": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "160", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160_a_i&doctype=Standard", "URIDate": "2025-03-27" }, "r83": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "160", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160_a_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r84": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "160", "Subparagraph": "a", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160_a_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r85": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "160", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160_a&doctype=Standard", "URIDate": "2025-03-27" }, "r86": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "160", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160&doctype=Standard", "URIDate": "2025-03-27" }, "r87": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "164", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_164_b&doctype=Standard", "URIDate": "2025-03-27" }, "r88": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "166", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_166_c&doctype=Standard", "URIDate": "2025-03-27" }, "r89": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "166", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_166&doctype=Standard", "URIDate": "2025-03-27" }, "r90": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "168", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_168_b_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r91": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "169", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_169&doctype=Standard", "URIDate": "2025-03-27" }, "r92": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "180", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_180_b&doctype=Standard", "URIDate": "2025-03-27" }, "r93": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "192", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_192&doctype=Standard", "URIDate": "2025-03-27" }, "r94": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "194", "Subparagraph": "c", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_194_c_i&doctype=Standard", "URIDate": "2025-03-27" }, "r95": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "194", "Subparagraph": "c", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_194_c_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "200", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_200_e&doctype=Standard", "URIDate": "2025-03-27" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "200", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_200&doctype=Standard", "URIDate": "2025-03-27" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "218", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_218_a&doctype=Standard", "URIDate": "2025-03-27" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "218", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_218_b&doctype=Standard", "URIDate": "2025-03-27" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "24", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_24_a&doctype=Standard", "URIDate": "2025-03-27" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "24", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_24_b&doctype=Standard", "URIDate": "2025-03-27" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "266", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_266&doctype=Standard", "URIDate": "2025-03-27" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_28_a_i&doctype=Standard", "URIDate": "2025-03-27" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_28_a_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "66", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_66&doctype=Standard", "URIDate": "2025-03-27" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "71", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_71&doctype=Standard", "URIDate": "2025-03-27" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "95", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_95_a&doctype=Standard", "URIDate": "2025-03-27" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "95", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_95_b&doctype=Standard", "URIDate": "2025-03-27" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B10", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10_a_i&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B10", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10_a_ii&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B10", "Subparagraph": "a", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10_a_iii&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B10", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10_a&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B10", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B9", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_f&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "103", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_103&doctype=Standard", "URIDate": "2025-03-27" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_a&doctype=Standard", "URIDate": "2025-03-27" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "Subparagraph": "d", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_d_i&doctype=Standard", "URIDate": "2025-03-27" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "Subparagraph": "d", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_d_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "Subparagraph": "d", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_d_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106&doctype=Standard", "URIDate": "2025-03-27" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_35&doctype=Standard", "URIDate": "2025-03-27" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_a&doctype=Standard", "URIDate": "2025-03-27" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_g&doctype=Standard", "URIDate": "2025-03-27" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_i&doctype=Standard", "URIDate": "2025-03-27" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "n", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_n&doctype=Standard", "URIDate": "2025-03-27" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "55", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_55&doctype=Standard", "URIDate": "2025-03-27" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "66", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_66&doctype=Standard", "URIDate": "2025-03-27" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "69", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_69&doctype=Standard", "URIDate": "2025-03-27" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "7", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_7&doctype=Standard", "URIDate": "2025-03-27" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_e&doctype=Standard", "URIDate": "2025-03-27" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a_i&doctype=Standard", "URIDate": "2025-03-27" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "a", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a&doctype=Standard", "URIDate": "2025-03-27" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "79", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79&doctype=Standard", "URIDate": "2025-03-27" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "81A", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_81A_a&doctype=Standard", "URIDate": "2025-03-27" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "81A", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_81A_b&doctype=Standard", "URIDate": "2025-03-27" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "81A", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_81A_c&doctype=Standard", "URIDate": "2025-03-27" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "82", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_82_a&doctype=Standard", "URIDate": "2025-03-27" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "82", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_82_b&doctype=Standard", "URIDate": "2025-03-27" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "82", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_82_d&doctype=Standard", "URIDate": "2025-03-27" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "91", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_91_a&doctype=Standard", "URIDate": "2025-03-27" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "99", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_99&doctype=Standard", "URIDate": "2025-03-27" }, "r144": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "37", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_37_a&doctype=Standard", "URIDate": "2025-03-27" }, "r145": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "32", "IssueDate": "2025-01-01", "Paragraph": "IE33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=32&code=ifrs-tx-2025-en-r&anchor=para_IE33&doctype=Illustrative%20Examples", "URIDate": "2025-03-27" }, "r146": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "14", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_14_f&doctype=Standard", "URIDate": "2025-03-27" }, "r147": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "16", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_16_a&doctype=Standard", "URIDate": "2025-03-27" }, "r148": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "17", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_17_a&doctype=Standard", "URIDate": "2025-03-27" }, "r149": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "17", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_17_d&doctype=Standard", "URIDate": "2025-03-27" }, "r150": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "17", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_17_e&doctype=Standard", "URIDate": "2025-03-27" }, "r151": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "44C", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_44C&doctype=Standard", "URIDate": "2025-03-27" }, "r152": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "44D", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_44D&doctype=Standard", "URIDate": "2025-03-27" }, "r153": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Section": "A Statement of cash flows for an entity other than a financial institution", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_A_TI", "URIDate": "2025-03-27" }, "r154": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Section": "C Reconciliation of liabilities arising from financing activities", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_C_TI", "URIDate": "2025-03-27" }, "r155": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B10", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r156": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "B6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_B6&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r157": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "IE63", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_IE63&doctype=Illustrative%20Examples", "URIDate": "2025-03-27" }, "r158": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "15", "IssueDate": "2025-01-01", "Paragraph": "B89", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_B89_f&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r159": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "113", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_113_b&doctype=Standard", "URIDate": "2025-03-27" }, "r160": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "23", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23&doctype=Standard", "URIDate": "2025-03-27" }, "r161": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_b&doctype=Standard", "URIDate": "2025-03-27" }, "r162": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "103", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_103_f&doctype=Standard", "URIDate": "2025-03-27" }, "r163": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B9", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_b&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r164": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B9", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_c&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r165": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B9", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_f&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r166": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "102", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_102&doctype=Standard", "URIDate": "2025-03-27" }, "r167": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "103", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_103&doctype=Standard", "URIDate": "2025-03-27" }, "r168": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "108", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_108&doctype=Standard", "URIDate": "2025-03-27" }, "r169": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "68", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_68&doctype=Standard", "URIDate": "2025-03-27" }, "r170": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_b&doctype=Standard", "URIDate": "2025-03-27" }, "r171": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_c&doctype=Standard", "URIDate": "2025-03-27" }, "r172": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_e&doctype=Standard", "URIDate": "2025-03-27" }, "r173": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r174": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "37", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2025-en-r&anchor=para_37&doctype=Standard", "URIDate": "2025-03-27" }, "r175": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "17", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_17&doctype=Standard", "URIDate": "2025-03-27" }, "r176": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "20", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_20_a&doctype=Standard", "URIDate": "2025-03-27" }, "r177": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "20", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_20_b&doctype=Standard", "URIDate": "2025-03-27" }, "r178": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "20", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_20_c&doctype=Standard", "URIDate": "2025-03-27" }, "r179": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "20", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_20&doctype=Standard", "URIDate": "2025-03-27" }, "r180": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "31", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_31&doctype=Standard", "URIDate": "2025-03-27" }, "r181": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_45&doctype=Standard", "URIDate": "2025-03-27" }, "r182": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "7", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_7&doctype=Standard", "URIDate": "2025-03-27" }, "r183": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "10", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_10_e&doctype=Standard", "URIDate": "2025-03-27" }, "r184": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "102", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_102&doctype=Standard", "URIDate": "2025-03-27" }, "r185": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "103", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_103&doctype=Standard", "URIDate": "2025-03-27" }, "r186": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_d&doctype=Standard", "URIDate": "2025-03-27" }, "r187": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "112", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_112_c&doctype=Standard", "URIDate": "2025-03-27" }, "r188": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "55", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_55&doctype=Standard", "URIDate": "2025-03-27" }, "r189": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_b&doctype=Standard", "URIDate": "2025-03-27" }, "r190": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78&doctype=Standard", "URIDate": "2025-03-27" }, "r191": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a&doctype=Standard", "URIDate": "2025-03-27" }, "r192": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "85", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_85&doctype=Standard", "URIDate": "2025-03-27" } } }